FY20 NAV STATEMENT HIGHLIGHTS[12] (2020 NUMBERS ARE UNAUDITED)

GEL '000, unless otherwise noted	Dec-19	1. Value creation[13]	2a. Investment	2b. Buyback	2c. Dividend	2d. GHG de-listing[14]	3.Operating expenses	4. Liquidity/ FX/Other	Dec-20	Change %
Total Listed Portfolio Value	1,027,814	(261,524)	138,265	-	-	(372,997)	-	-	531,558	-48.3%
Listed Portfolio value change %		-25.4%	13.5%	0.0%	0.0%	-36.3%	0.0%	0.0%	-48.3%
Total Private Portfolio Value	1,225,269	741,009	56,400	-	(29,870)	372,997	-	10,325	2,376,130	93.9%
Of which, Large Companies	648,893	859,545	-	-	(24,943)	372,997	-	1,745	1,858,237	NMF
Of which, Investment Stage Companies	163,150	98,730	44,501	-	(4,927)	-	-	1,510	302,964	85.7%
Of which, Other Companies	413,226	(217,266)	11,899	-	-	-	-	7,070	214,929	-48.0%
Private Portfolio value change %		60.5%	4.6%	0.0%	-2.4%	30.4%	0.0%	0.8%	93.9%
Total Portfolio Value (1)	2,253,083	479,485	194,665	-	(29,870)	-	-	10,325	2,907,688	29.1%
Total Portfolio value change %		21.3%	8.6%	0.0%	-1.3%	0.0%	0.0%	0.5%	29.1%
Net Debt (2)	(493,565)	-	(57,684)	(6,033)	29,870	-	(19,455)	(151,132)	(697,999)	41.4%
Net Asset Value (1)+(2)+(3)	1,753,868	479,485	138,265	(6,033)	-	-	(32,136)	(121,157)	2,212,292	26.1%
NAV change %		27.3%	7.9%	-0.3%	0.0%	0.0%	-1.8%	-6.9%	26.1%
Shares outstanding13	37,441,971	-	7,734,010	(173,076)	-	-	-	974,342	45,977,247	22.8%
Net Asset Value per share, GEL	46.84	12.81	(4.96)	0.06	0.00	0.00	(0.86)	(5.78)	48.12	2.7%
NAV per share, GEL change %		27.3%	-10.6%	0.1%	0.0%	0.0%	-1.8%	-12.3%	2.7%

 

Importantly in this pandemic year, NAV per share (GEL) increased by 2.7% in FY20, with the two biggest impacts being (i) the minority shareholder buy-out and subsequent revaluation of GHG (resulting in GHG becoming a private company in 3Q20 and being valued together with the rest of our private portfolio) and (ii) the mainly COVID-related valuation declines of our "other" private portfolio businesses. The main positive and negative contributors to the overall increase were:

₋     The valuation and buy-out of GHG had an aggregate 24.8% impact on the NAV per share in FY20

₋     The first time valuation and subsequent revaluations of our investment stage portfolio companies had in aggregate 5.6% impact on NAV per share in FY20

₋     Valuations declined across our "other" private portfolio companies (-12.4% impact on the NAV per share), primarily reflecting the negative impact of COVID-19 on Hospitality and Commercial Real Estate business. In addition, reduced valuation of BoG had a negative 3.8% impact on the NAV per share

₋     NAV per share was further impacted by: a) GEL depreciation against USD by 14.3%, resulting in a foreign exchange loss of GEL 90.9 million on GCAP net debt (-5.2% impact); b) management platform related costs (-1.8% impact); c) net interest expense and fair value losses on liquid assets (-2.5% impact); and d) other individually immaterial items (in aggregate -2.0% impact).  

Portfolio overview

Our portfolio value increased by 29.1% to GEL 2.9 billion in FY20, reflecting a 48.3% decline and 93.9% growth in the value of listed and private businesses, respectively. The value of our investment in the listed assets decreased by GEL 496 million during FY20 mainly reflecting the de-listing and transfer of GHG to the private portfolio. The market value of our 100% holding in GHG was GEL 373 million on the de-listing date of 5-Aug-20 ("cost of GHG investment" or "cost"). The value of our private portfolio companies increased by GEL 1.2 billion in FY20 reflecting the transfer of GHG at GEL 373 million cost, the addition of GEL 741.1 million due to value creation across the total private portfolio, the increase of GEL 56.4 million due to investments and the decrease of GEL 29.9 million due to dividends received from private portfolio companies.

1)    Value creation

The negative value creation on listed assets was GEL 261.5 million, of which GEL 195.3 million was driven by negative value creation on our holding in GHG before de-listing and GEL 66.2 million by a 24.9% decrease in the BoG share price in FY20 to GBP 12.20. The value creation of GEL 741.1 million on the private portfolio reflects: a) GEL 676.1 million from greenfields / buy-outs, driven by the first time valuation of GHG following buy-out in 3Q20 (GEL 620.0 million) and the first time valuation of investment stage portfolio companies in 1H20 (GEL 57.1 million); b) GEL 62.1 million operating performance-related net decrease in the value of our private assets in aggregate, primarily reflecting the negative impact of COVID-19 on LTM earnings; and c) GEL 127.1 million net increase from movements in valuation multiples and foreign currency exchange rates. The table below summarises value creation drivers in our businesses in FY20.

 

 

Portfolio Businesses	Operating Performance[15]	Greenfields / buy-outs[16]	Multiple Change  and FX[17]	Value Creation
Unaudited numbers, in GEL '000	(1)	(2)	(3)	(1)+(2)+(3)
Listed				(261,524)
GHG				(195,347)
BoG				(66,177)
Private	(62,130)	676,069	127,070	741,009
Large Portfolio Companies	89,997	620,003	149,545	859,545
Healthcare Services	40,279	295,641	57,877	393,797
Retail (pharmacy)	53,276	296,577	24,469	374,322
Water Utility	(7,153)	-	7,586	433
Insurance (P&C and Medical)	3,595	27,785	59,613	90,993
Of which, P&C Insurance	(4,818)	-	47,644	42,826
Of which, Medical Insurance	8,413	27,785	11,969	48,167
Investment Stage Portfolio Companies	35,292	57,067	6,371	98,730
Renewable Energy	22,399	32,720	7,050	62,169
Education	12,893	24,347	(679)	36,561
Other	(187,419)	(1,001)	(28,846)	(217,266)
Total portfolio	(62,130)	676,069	127,070	479,485

 

2) Investments[18]

During the pandemic we implemented a cash accumulation and preservation strategy and put our capital allocations on hold and made only limited investments. The following capital allocations were made in FY20:

₋     GEL 138 million equity capital allocation was related to the buy-out of the minority shareholders in GHG. This was paid for by the exchange of newly issued 7.7 million CGEO shares into GHG shares valued at GEL 138 million.

₋     GEL 44.4 million was allocated to Renewable Energy, of which, GEL 38.7 million was for the buyout of the minority shareholder in February 2020 and GEL 5.6 million for the development of pipeline HPPs.

₋     GEL 5.0 million was allocated to Beverages to finance working capital needs of the beer business.

₋     GEL 4.2 million was allocated to Auto Service, for the working capital financing and the buyout of an additional 10% equity stake in Amboli, increasing GCAP's total ownership to 90%.

3) Dividends¹⁸

In FY20, Georgia Capital collected GEL 30 million dividends, of which: GEL 5 million was received from Renewable Energy; GEL 10 million - from P&C Insurance and GEL 15 million - from Water Utility.

Net debt overview

Net debt increased by 41.4% to GEL 698 million in FY20, with the increase being driven primarily by a foreign exchange loss of GEL 90.9 million. The net debt was further impacted by: a) GEL 57.7 million cash outflows for investments; b) net interest expense and fair value gains on liquid funds, driving net GEL 44.5 million increase in net debt; c) GCAP cash operating expenses of GEL 19.5 million; d) GEL 29.9 million dividend inflows from portfolio companies. In addition, in 2020 Georgia Capital collected net cash from the repayment of the following loans: US$ 13 million issued to Renewable Energy, refinanced by the proceeds raised from the Green Bond issuance in Jul-20 and US$ 12 million issued to BoG's holding company as part of the demerger. As a result, the issued loan balance decreased by 28.2% in 2020. The table below summarises components of net debt as of 31 December 2020 and as of 31 December 2019:

GE    Unaudited numbers, in GEL '000	31-Dec-20	31-Dec-19	Change
Cash at banks	160,536	118,458	35.5%
Internationally listed debt securities	14,098	69,712	-79.8%
Locally listed debt securities	655	23,719	-97.2%
Loans issued	108,983	151,884	-28.2%
Total Cash and liquid funds (a)	284,272	363,773	-21.9%
Gross Debt (b)	(982,271)	(857,338)	14.6%
Net debt (a)+(b)	(697,999)	(493,565)	41.4%

 

 

 

 

INCOME STATEMENT (ADJUSTED IFRS / APM)

Net income under IFRS was GEL 480 million in 4Q20 (GEL 330 million in FY20). The IFRS income statement is prepared on the Georgia Capital PLC level and the results of all operations of the Georgian holding company JSC Georgia Capital are presented as one line item. As we conduct most of our operations through JSC Georgia Capital, through which we hold our portfolio companies, the IFRS results provide little transparency on the underlying trends.

Accordingly, to enable a more granular analysis of those trends, the following adjusted income statement presents the Group's results of operations for the period ending December 31 as an aggregation of (i) the results of GCAP (the two holding companies Georgia Capital PLC and JSC Georgia Capital, taken together) and (ii) the fair value change in the value of portfolio companies during the reporting period. For details on the methodology underlying the preparation of the adjusted income statement, please refer to page 90 in Georgia Capital PLC 2019 Annual report. A full reconciliation of the adjusted income statement to the IFRS income statement is provided on page 21.

 

INCOME STATEMENT (Adjusted IFRS/APM, unaudited)

GEL '000, unless otherwise noted	4Q20	4Q19	Change	FY20	FY19	Change
Dividend income	14,972	35,943	-58.3%	29,870	122,219	-75.6%
Interest income	4,307	7,647	-43.7%	20,957	39,044	-46.3%
Realised / unrealised (loss)/ gain on liquid funds	1,119	3,596	-68.9%	(2,984)	9,547	NMF
Interest expense	(16,537)	(14,610)	13.2%	(62,478)	(55,071)	13.4%
Gross operating (loss)/income	3,861	32,576	-88.1%	(14,635)	115,739	NMF
Operating expenses	(9,109)	(9,032)	0.9%	(32,136)	(34,391)	-6.6%
GCAP net operating (loss)/income	(5,248)	23,544	NMF	(46,771)	81,348	NMF
Fair value changes of portfolio companies
Listed portfolio companies	171,458	(105,463)	NMF	(261,524)	(62,869)	NMF
Of which, Georgia Healthcare Group PLC	-	(228,422)	NMF	(195,347)	(203,109)	-3.8%
Of which, Bank of Georgia Group PLC	171,458	122,959	39.4%	(66,177)	140,240	NMF
Private portfolio companies	323,699	(5,412)	NMF	711,139	75,021	NMF
Large Portfolio Companies	312,198	(4,555)	NMF	834,602	87,352	NMF
Of which, Healthcare Services	98,156	-	NMF	393,797	-	NMF
Of which, Retail (pharmacy)	77,745	-	NMF	374,322	-	NMF
Of which, Water Utility	58,614	(9,649)	NMF	(14,567)	52,953	NMF
Of which, Insurance (P&C and Medical)	77,683	5,094	NMF	81,050	34,399	NMF
Investment Stage Portfolio Companies	20,481	-	NMF	93,803	-	NMF
Of which, Renewable energy	8,185	-	NMF	57,242	-	NMF
Of which, Education	12,296	-	NMF	36,561	-	NMF
Other businesses	(8,980)	(857)	NMF	(217,266)	(12,331)	NMF
Total investment return	495,157	(110,875)	NMF	449,615	12,152	NMF
(Loss)/Income before foreign exchange movements and non-recurring expenses	489,909	(87,331)	NMF	402,844	93,500	NMF
Net foreign currency loss	(14,421)	18,280	NMF	(90,943)	(20,967)	NMF
Non-recurring expenses	(166)	(982)	-83.1%	(3,389)	(982)	NMF
Net Income/(loss) (adjusted IFRS)	475,322	(70,033)	NMF	308,512	71,551	NMF

An 88.1% y-o-y decrease in 4Q20 gross operating income to GEL 3.9 million and FY20 gross operating loss of GEL 14.6 million mainly reflect decreased dividend inflows due to COVID-19 related uncertainties. The dividend income by businesses is presented in the table below:

GEL '000, unless otherwise noted	4Q20	4Q19	Change	FY20	FY19	Change
Water Utility	10,000	22,000	-54.5%	15,000	22,000	-31.8%
P&C Insurance	4,972	4,033	23.3%	9,943	12,033	-17.4%
Renewable Energy	-	-	NMF	4,927	-	NMF
BoG	-	-	NMF	-	24,951	NMF
GHG	-	-	NMF	-	3,981	NMF
Housing Development	-	9,910	NMF	-	59,254[19]	NMF
Total dividend income	14,972	35,943	-58.3%	29,870	122,219	-75.6%

Further, interest income was down 43.7% to GEL 4.3 million in 4Q20 and down 46.3% in FY20 to GEL 21.0 million, in line with decrease in the average balance of liquid funds. GCAP earned an average yield of 6.7% on the average balance of liquid assets and issued loans of GEL 277.3 million in FY20 (7.6% on GEL 451.5 million in FY19). The coupon on the 6-year US$ 300 million bond, issued in Mar-18, is 6.125%. As a result, net interest expense was GEL 12.2 million and GEL 41.5 million in 4Q20 and FY20 at GCAP level, respectively (GEL 6.9 million in 4Q19 and GEL 16.0 million in FY19).

GCAP management fee expenses have a self-targeted cap of 2% of Georgia Capital's market capitalisation. The LTM management fee expense ratio was 1.8% at 31-Dec-20 (1.8%[20] as of 31-Dec-19). The total LTM operating expense ratio (which includes fund type expenses) was 2.8% at 31-Dec-20 (2.4%²⁰ at 31-Dec-19). The expense ratio reflects the negative impact of COVID-19 on Georgia Capital's share price. The components of GCAP's operating expenses are presented in the table below:

GEL '000, unless otherwise noted	4Q20	4Q19	Change	FY20	FY19	Change
Administrative expenses[21]	(2,933)	(3,388)	-13.4%	(10,477)	(11,542)	-9.2%
Management expenses - cash-based[22]	(2,969)	(2,076)	43.0%	(8,978)	(8,327)	7.8%
Management expenses - share-based[23]	(3,207)	(3,568)	-10.1%	(12,681)	(14,522)	-12.7%
Total operating expenses	(9,109)	(9,032)	0.9%	(32,136)	(34,391)	-6.6%
Of which, fund type expense[24]	(3,093)	(2,592)	19.3%	(11,030)	(9,163)	20.4%
Of which, management fee[25]	(6,016)	(6,440)	-6.6%	(21,106)	(25,228)	-16.3%

 

Total investment return represents the increase (decrease) in the fair value of our portfolio. Total investment return was GEL 495.2 million in 4Q20 and GEL 449.6 million in FY20, reflecting growth in the value of listed and private businesses, as described earlier in this report. We discuss valuation drivers for our businesses on pages 4-8. The performance of each of our private large and investment stage portfolio companies is discussed on pages 11-20. In 4Q20, total investment return of GEL 495.2 million and dividend income of GEL 15.0 million together led to GEL 510.1 million value creation as presented in the 4Q20 NAV statement on page 3. In FY20, total investment return of GEL 449.6 million and dividend income of GEL 29.9 million together led to GEL 479.5 million value creation as presented in the FY20 NAV highlights on page 7.

The Group's net income (adjusted IFRS) is then driven by net foreign currency loss, reflecting the impact of GEL devaluation against the US dollar on GCAP's net foreign currency liability balance amounting to c. US$ 219 million (GEL 718 million) at 31-Dec-20. Net foreign currency loss was GEL 14.4 million and GEL 90.9 million, respectively, in 4Q20 and FY20. As a result of the movements described above, GCAP's adjusted IFRS net income was GEL 475.3 million in 4Q20 and GEL 308.5 million in FY20. See page 21 for a reconciliation to the IFRS figures presented above. 

 

 

 

DISCUSSION OF PORTFOLIO COMPANIES' RESULTS (STAND-ALONE IFRS)

The following sections present the IFRS results and business development derived from the individual portfolio company's IFRS accounts for large and investment stage entities, where 2020 portfolio company's accounts and respective IFRS numbers are unaudited. We present key IFRS financial highlights, operating metrics and ratios along with the commentary explaining the developments behind the numbers. For the majority of our portfolio companies the fair value of our equity investment is determined by the application of a market approach (listed peer multiples and precedent transactions) and an income approach (DCF). Under the market approach, listed peer group earnings multiples are applied to the trailing twelve months (LTM) stand-alone IFRS earnings of the relevant business. Under the discounted cash flow (DCF) valuation method, fair value is estimated by deriving the present value of the business using reasonable assumptions of expected future cash flows and the terminal value, and the appropriate risk-adjusted discount rate that quantifies the risk inherent to the business. As such, the stand-alone IFRS results and developments driving the IFRS earnings of our portfolio companies are key drivers of their valuations within GCAP's financial statements. See "Basis of Presentation" for more background on pages 29-30.

 

 

LARGE PORTFOLIO COMPANIES

Discussion of Healthcare Services Business Results

Healthcare Services business, owned through GHG, is the largest healthcare market participant in Georgia, accounting for 20% of the country's total hospital bed capacity as of 31-Dec-20. Healthcare services business comprises three segments: 1) Hospitals (17 referral hospitals with a total of 2,596 beds) providing secondary and tertiary level healthcare services; 2) Clinics: 19 community clinics with 353 beds (providing outpatient and basic inpatient services) and 15 polyclinics (providing outpatient diagnostic and treatment services); 3) Diagnostics, operating the largest laboratory in the entire Caucasus region - "Mega Lab". Following GHG de-listing and the buy-out of the 29.4% minority stake in 3Q20, the healthcare services business is 100% owned by Georgia Capital.

 

4Q20 & FY20 performance (GEL '000), Healthcare Services[26]^,[27]

2020 numbers are unaudited
INCOME STATEMENT HIGHLIGHTS	4Q20	4Q19		Change		FY20			FY19			Change
Revenue, net[28]	84,497	74,596		13.3%		283,447			290,758			-2.5%
Gross Profit	31,245	32,258		-3.1%		111,919			125,751			-11.0%
Gross profit margin	36.8%	43.1%		-6.3ppts		39.2%			42.9%			-3.7ppts
Operating expenses (ex. IFRS 16)	(10,565)	(11,232)		-5.9%		(50,093)			(51,040)			-1.9%
EBITDA (ex. IFRS 16)	20,680	21,026		-1.6%		61,826			74,711			-17.2%
EBITDA margin (ex. IFRS 16)	24.3%	28.1%		-3.7ppts		21.6%			25.5%			-3.9ppts
Adjusted[29] net profit ex. IFRS 16	7,870	6,128		28.4%		4,877			17,627			-72.3%
CASH FLOW HIGHLIGHTS
Cash flow from operating activities (ex. IFRS 16)	7,933	30,891		-74.3%			80,956			59,645			35.7%
EBITDA to cash conversion (ex. IFRS 16)	38.4%	146.9%		-108.5ppts			130.9%			79.8%			51.1ppts
Cash flow from/used in investing activities[30]	(972)	(619)		57.1%			16,755			(14,062)			NMF
Free cash flow (ex. IFRS 16)[31]	(29)	23,991		NMF			83,528			23,295			258.6%
Cash flow from financing activities (ex. IFRS 16)	(12,143)	(25,631)		-52.6%			(15,169)			(54,095)			-72.0%
BALANCE SHEET HIGHLIGHTS	31-Dec-20		30-Sep-20		Change			31-Dec-19			Change
Total assets	899,391		885,943		1.5%			953,874			-5.7%
Of which, cash balance and bank deposits	93,721		98,905		-5.2%			7,648			NMF
Of which, securities and loans issued	7,133		4,573		56.0%			-			NMF
Total liabilities	510,079		491,708		3.7%			472,675			7.9%
Of which, borrowings	312,036		313,853		-0.6%			291,239			7.1%
Total equity	389,312		394,235		-1.2%			481,199			-19.1%

KEY POINTS / VALUATION DRIVERS

Ø Revenue demonstrating strong growth trajectory in 4Q20, up 13.3% y-o-y (down slightly in FY20 by 2.5% y-o-y)

Ø 4Q20 EBITDA remained largely flat y-o-y at GEL 20.7 million (GEL 61.8 million in FY20, down 17.2% y-o-y)

Ø Free cash flow (excl. IFRS 16) at GEL 83.5 million in FY20, up 258.6% y-o-y

Ø Net debt[32] down 25.5% y-o-y to GEL 211.2 million as of 31-Dec-20 (up 0.4% q-o-q reflecting FX impact)

INCOME STATEMENT HIGHLIGHTS

Following the lifting of COVID-19 related lockdown restrictions in June, which affected hospitals and clinics segments, the healthcare business revenue started to rebound and the trend continued throughout the second half of 2020. Since September 2020, due to the increased spread of the COVID-19 virus, the business has mobilised ten healthcare facilities, four clinics and six hospitals to receive COVID patients only, and ten healthcare facilities as hybrid ones, focused on both COVID and non-COVID patients, with total aggregate number of c. 1,300 beds across the country. The Government of Georgia fully reimburses costs associated with COVID-19 treatments, and also pays a fixed fee amount per each occupied bed for COVID patient.

₋     The number of admissions was up by 9.3% at clinics in 4Q20 y-o-y, translating into 4Q20 net revenue of GEL 13.5 million, up 14.0% y-o-y.

₋     Similarly, the occupancy rate was up by 3.6 ppts in 4Q20 y-o-y in hospitals. Despite the fact that since the October Ministry of Health and Social Affairs temporarily suspended the issuance of guarantee letters for elective care treatments, the increased occupancy rate translated into a 4.6% y-o-y net revenue growth to GEL 65.7 million in 4Q20.

₋     The diagnostics segment, which apart from regular diagnostics services is also engaged in COVID-19 testing, more than quadrupled its quarterly revenue in 4Q20 y-o-y to GEL 7.8 million.

The developments described above translated into 13.3% y-o-y growth in 4Q20 net revenue from healthcare services. FY20 healthcare services net revenue was slightly down (2.5% y-o-y), reflecting a reduction in patient footfall at healthcare facilities mainly during the COVID-19 lockdown in 2Q20.

The cost of services in the business are captured in the materials and direct salary rates. In 4Q20 and FY20, direct salary rate remained well-controlled at hospitals (down 2.8 ppts and 0.6 ppts y-o-y) and clinics (down 4.8 ppts and 3.0 ppts y-o-y). The direct salary rate partially benefited from 6-months state income tax subsidy for low salary range employees (salary up to GEL 750), declared in May. The materials rate increased in 2020 (up 8.4 ppts and 4.1 ppts at hospitals and up 2.9 ppts and 1.1 ppts at clinics in 4Q20 and FY20, respectively), reflecting local currency exchange rate depreciation as well as increased consumption of medical disposables and personal protective equipment at healthcare facilities due to COVID-19. As a result, the healthcare services gross margin was subdued by 6.3 ppts for 4Q20 and 3.7 ppts for FY20, y-o-y. Due to the cost optimization measures, the business posted positive 2.8 ppts operating leverage in 4Q20, translating into a GEL 20.7 million EBITDA earnings excluding IFRS 16 (down 1.6% y-o-y). In 4Q20, EBITDA margin (excl. IFRS 16) was 24.8% at hospitals and 22.5% at clinics, both subdued mainly due to the increased direct cost of materials explained above. Overall, in FY20, the business posted GEL 61.8 million EBITDA (excl. IFRS 16), down 17.2% y-o-y.

Strong liquidity management measures resulted in a 25.5% y-o-y decline in the net debt position to GEL 211.2 million as of 31-Dec-20, which reduced interest expense (excl. IFRS 16) y-o-y by 34.4% in 4Q20 to GEL 5.1 million and by 8.5% for FY20 to GEL 27.4 million. The GEL depreciation during 2020 led to a foreign currency loss (GEL 2.0 million in 4Q20 and GEL 5.1 million in FY20 excl. IFRS 16) on the relatively small portion of the business's borrowings denominated in foreign currency. The business had non-recurring expenses of GEL 11.0 million in FY20, mainly related to one-off costs associated with de-listing of GHG from London Stock Exchange, of which, GEL 4.6 million relates to acceleration of share-based expenses for employees and GEL 4.1 million to legal and other fees. The business posted net profit from continuing operations of GEL 3.7 million in 4Q20 and net loss of GEL 11.2 million in FY20 excluding IFRS 16, which adjusted for FX loss and non-recurring expenses resulted in net profit of GEL 7.9 million for 4Q20 (up 28.4% y-o-y) and GEL 4.9 million for FY20 (down 72.3% y-o-y). In FY20, a loss from discontinued operations of GEL 26.1 million was recorded, resulting from the disposal of a 40% equity stake in HTMC.

CASH FLOW HIGHLIGHTS

In line with management's expectations, 4Q20 was a weak quarter in terms of operating cash flow generation. It was both the collection quarter for the lower revenues generated during the 2Q20 lockdown period, as well as the payment quarter for GEL 5.0 million of 6-months of accumulated income tax deferred pursuant to a state initiative declared in May. Overall, cash collection from the Government and strong liquidity management practices led to an increase in cash flow generation in 2020, with 130.9% cash conversion ratio, up 51.1 ppts y-o-y, excluding IFRS 16. Strong operating cash flow excl. IFRS 16 (up 35.7% y-o-y to GEL 81.0 million in FY20), reduced capex investments (down 18.6% y-o-y from GEL 30.2 million in FY19) and GEL 32.8 million net proceeds received from selling the HTMC hospital, resulted in GEL 93.7 million ending cash and cash equivalent balance as of 31 December 2020 (up from GEL 7.6 million at 31-Dec-19). At the same time, free cash flow, excluding IFRS 16, increased significantly to GEL 83.5 million in FY20 (up from GEL 23.3 million y-o-y).

 

 

 

Discussion of Retail (pharmacy) Business Results

Retail (pharmacy) business, owned through GHG, is the largest pharmaceuticals retailer and wholesaler in Georgia, with a c.33% market share by revenue. The business consists of a retail pharmacy chain and a wholesale business that sells pharmaceuticals and medical supplies to hospitals and other pharmacies. The pharmacy chain has a total of 313 pharmacies, of which, 309 are in Georgia and 4 are in Armenia. Following GHG de-listing and the buy-out of the 29.4% minority stake in 3Q20, GCAP owns 67% in the retail (pharmacy) business.

 

4Q20 & FY20 performance (GEL '000), Retail (pharmacy)[33]

2020 numbers are unaudited
INCOME STATEMENT HIGHLIGHTS	4Q20	4Q19	Change	FY20	FY19	Change
Revenue, net	201,004	172,682	16.4%	679,437	614,675	10.5%
Gross Profit	48,741	44,921	8.5%	172,312	156,855	9.9%
Gross profit margin	24.2%	26.0%	-1.8ppts	25.4%	25.5%	-0.1ppts
Operating expenses (ex. IFRS 16)	(28,414)	(25,736)	10.4%	(101,925)	(91,552)	11.3%
EBITDA (ex. IFRS 16)	20,327	19,185	6.0%	70,387	65,303	7.8%
EBITDA margin, (ex. IFRS 16)	10.1%	11.1%	-1.0ppts	10.4%	10.6%	-0.2ppts
Net profit (ex. IFRS 16)	12,082	16,185	-25.4%	32,531	46,590	-30.2%
CASH FLOW HIGHLIGHTS
Cash flow from operating activities (ex. IFRS 16)	17,635	33,413	-47.2%	66,075	53,129	24.4%
EBITDA to cash conversion	86.8%	174.2%	-87.4ppts	93.9%	81.4%	+12.5ppts
Cash flow used in investing activities	(938)	(12,806)	-92.7%	(1,963)	(13,718)	-85.7%
Free cash flow, (ex. IFRS 16)[34]	16,150	29,682	-45.6%	60,760	47,565	27.7%
Cash flow from financing activities (ex. IFRS 16)	(15,569)	(18,384)	-15.3%	(37,091)	(48,711)	-23.9%
BALANCE SHEET HIGHLIGHTS	31-Dec-20	30-Sep-20	Change	31-Dec-19	Change
Total assets	464,644	435,178	6.8%	396,078	17.3%
Of which, cash and bank deposits	36,856	35,918	2.6%	7,774	NMF
Of which, securities and loans issued	12,471	12,398	0.6%	12,167	2.5%
Total liabilities	361,048	346,204	4.3%	303,240	19.1%
Of which, borrowings	88,608	94,612	-6.3%	84,712	4.6%
Of which, lease liabilities	85,919	89,065	-3.5%	77,700	10.6%
Total equity	103,596	88,974	16.4%	92,838	11.6%

KEY POINTS / VALUATION DRIVERS

Ø Continued solid y-o-y growth in 4Q20 and FY20 revenues and EBITDA despite COVID-19 outbreak

Ø Achieved 10.1% EBITDA margin in 4Q20 and 10.4% in FY20, substantially exceeding the targeted 9%

Ø FY20 free cash flow at GEL 60.8 million, up 27.7% y-o-y

Ø Net debt[35] down 39.4% y-o-y to GEL 39.3 million as of 31-Dec-20 (down 15.2% q-o-q)

Ø Added 16 pharmacies over the last 12 months, expanding from 293 to 309 stores nationwide

INCOME STATEMENT HIGHLIGHTS

The pharmacy business continued to deliver revenue growth in 2020, reflecting both expansion and organic sales growth, with 9.2% and 6.1%, same-store revenue growth rates in 4Q20 and FY20, respectively. From April sales started to slow down after strong 1Q20 results, reflecting pandemic related behavioural change, as customers started to stock up on pharmaceuticals in March ahead of the lockdown. However, revenue rebounded in June and the trend continued in the fourth quarter. As a result, the business posted a 16.4% increase in net revenues in 4Q20 and overall, a 10.5% increase in FY20, y-o-y. The business issued 7.2 million bills in 4Q20 and 27.6 million in FY20, with average customer interactions of 2.3 million per month. The average bill size substantially increased to GEL 18.6 in 4Q20 (up 23.2% y-o-y) and GEL 16.8 in FY20 (up 17.9% y-o-y), reflecting para-pharmacy (personal care, beauty and other non-medication high margin products) sales promotions.

In 4Q20, the retail revenue share in total revenue was 70.8% (71.2% in 4Q19) and revenue from para-pharmacy as a percentage of retail revenue from pharma was up 4.4 ppts y-o-y (from 30.2% in 4Q19 to 34.6% in 4Q20). Revenues from para-pharmacy sales were up 45.8% y-o-y to GEL 58.0 million in 4Q20. The increase mainly reflects increased sale of personal protective items such as disinfectants, masks etc. and promotions on para-pharmacy products that slightly subdued the margins, translating into a 1.8 ppts y-o-y decrease in business gross margin to 24.2% in 4Q20. Overall, in FY20, the retail revenue share in total revenue was 72.8% (71.2% in FY19) and revenue from para-pharmacy as a percentage of retail revenue from pharma was 34.7% (31.0% in FY19). In FY20, revenues from para-pharmacy sales were up 29.7% y-o-y to GEL 186.3 million (GEL 143.6 million in FY19) and the business posted 25.4% gross margin (25.5% in FY19).

The negative operating leverage (1.9% in 4Q20 and 1.4% in FY20) mainly reflects the increased rent expense of pharmacies due to GEL devaluation throughout the year (about 85% of rental contracts are denominated in US$ dollars). The result was a 6.0% and 7.8% y-o-y growth in 4Q20 and FY20 EBITDA excluding IFRS 16, with a 10.1% and 10.4% EBITDA margins, respectively.

Interest expense, excluding IFRS 16, was down 15.8% y-o-y in 4Q20 to GEL 2.4 million and down 9.9% y-o-y in FY20 to GEL 10.6 million. As the inventory purchases are denominated in foreign currency (c. 40% in EUR and c. 30% in USD), devaluation of the local currency in 4Q20 and FY20 resulted in FX loss of GEL 3.5 and GEL 13.2 million, respectively, excluding IFRS 16. The business posted GEL 8.4 million net non-recurring expense in FY20, primarily related to one-off cost associated with GHG de-listing, of which, GEL 4.9 million relates to acceleration of share-based expenses for employees and GEL 2.0 million to legal and other fees. In addition, net non-recurring expenses include GEL 1.2 million charity costs to help Georgian doctors, who are engaged in fighting against COVID-19.

As a result, the business posted a GEL 12.1 million profit in 4Q20, excluding IFRS 16, which adjusted for FX loss and non-recurring expenses resulted in a 10.2% y-o-y increase in net profit to GEL 16.8 million. In FY20, the business posted GEL 32.5 million net profit excluding IFRS 16, which, if adjusted for FX loss and non-recurring expenses, resulted in an 8.9% y-o-y increase in net profit to GEL 54.1 million.

CASH FLOW AND BALANCE SHEET HIGHLIGHTS

4Q20 operating cash was affected by lump-sum payment of accumulated 6-months deferred income tax of GEL 4.5 million, similar to the healthcare services business. The strong operating cash flow with EBITDA to cash conversion ratio of 86.8% in 4Q20 and 93.9% in FY20, coupled with decreased capex investments, resulted in an ending balance of cash and cash equivalents of GEL 36.9 million as of 31-Dec-20 (up from GEL 7.8 million at 31-Dec-19). Free cash flow also increased significantly in FY20 to GEL 60.8 million, up 27.7%. Strong liquidity management was reflected in an improved leverage profile, with net debt being down 39.4% y-o-y as of 31-Dec-20.

 

 

Discussion of Water Utility Business Results

Our Water Utility is a regulated monopoly in Tbilisi and the surrounding area, where it provides water and wastewater services to 1.4 million residents representing more than one-third of Georgia's population and c. 37,000 legal entities. Water Utility also operates hydro power plants with a total installed capacity of 149 MW. GCAP owns 100% in Water Utility.

 

4Q20 & FY20 performance (GEL '000), Water Utility[36]

2020 numbers are unaudited
INCOME STATEMENT HIGHLIGHTS	4Q20	4Q19	Change	FY20	FY19	Change
Revenue	31,794	44,265	-28.2%	130,548	163,454	-20.1%
Water supply	30,585	38,671	-20.9%	124,651	143,237	-13.0%
Energy	1,209	5,594	-78.4%	5,897	20,217	-70.8%
Operating expenses	(18,089)	(15,771)	14.7%	(61,733)	(61,053)	1.1%
EBITDA	12,137	27,256	-55.5%	62,546	95,076	-34.2%
EBITDA margin	38.2%	61.6%	-23.4 ppts	47.9%	58.2%	-10.3 ppts
Net (loss)/profit	(15,784)	14,306	NMF	(61,082)	33,221	NMF
CASH FLOW HIGHLIGHTS
Cash flow from operating activities	21,764	20,278	7.3%	55,822	76,394	-26.9%
Cash flow used in investing activities	(16,635)	(14,793)	12.5%	(51,702)	(59,561)	-13.2%
Free cash flow	5,129	5,485	-6.5%	4,120	15,937	-74.1%
Cash flow from financing activities	(11,992)	(16,580)	-27.7%	21,861	(3,315)	NMF
BALANCE SHEET HIGHLIGHTS	31-Dec-20	30-Sep-20	Change	31-Dec-19	Change
Total assets	653,201	653,180	NMF	591,036	10.5%
Of which, cash balance	55,577	61,795	-10.1%	26,581	109.1%
Total liabilities	574,179	549,170	4.6%	432,741	32.7%
Of which, long-term borrowings	498,555	490,476	1.6%	353,021	41.2%
Total equity	79,022	104,010	-24.0%	158,295	-50.1%

KEY POINTS / VALUATION DRIVERS

Ø FY20 EBITDA down 34.2% y-o-y, reflecting COVID-19 related decrease in water consumption levels in corporate clients and low water inflows at Zhinvali reservoir

Ø Cash balance up 109.1% in 2020 to GEL 55.6 million, reflecting US$ 250 million green bond issuance in Jul-20

Ø New water tariffs set at the end of 2020, translating into a 38% increase in allowed revenues from water sales for the 2021-2023 regulatory period compared to the previous regulatory period of 2018-2020

Ø Cash flow from operating activities up 7.3% y-o-y in 4Q20 

INCOME STATEMENT HIGHLIGHTS

The 28.2 % y-o-y decrease in 4Q20 revenues (down 20.1% y-o-y in FY20) was primarily driven by a 78.4% decrease in energy revenues (down 70.8% y-o-y in FY20) and a 20.9% decrease in water sales revenues (down 13.0% y-o-y in FY20). Extraordinarily low precipitation related water inflows to Zhinvali HPP led to a 42.9% y-o-y decrease in electricity generation in 4Q20 (down 35.0% in FY20), while self-produced electricity consumption only decreased by 1.1% y-o-y (up 0.7% in FY20). As a result, 4Q20 electricity sales volume decreased by 80.6% y-o-y (down 69.9% in FY20). Revenue from water supply to legal entities was down 27.5% y-o-y to GEL 17.5 million in 4Q20 (down 18.0% y-o-y to GEL 76.7 million in FY20) reflecting the effects of COVID-19 and related decrease in business activities. Revenues from water supply to individuals remained broadly stable at GEL 9.5 million in 4Q20 (down 3.2% y-o-y) and GEL 38.8 million in FY20 (down 2.5% y-o-y).

According to the water tariff setting methodology, sales volume risk does not stay with the company and unearned revenues in 2018-2020 regulatory period were fully reimbursed through the new tariffs for the 2021-2023 regulatory period. In December 2020, the regulator approved water supply and sanitation ("WSS") tariffs (set per m³ of WSS services supplied) in Tbilisi, which have increased compared to the previous regulatory period of 2018-2020: i) from GEL 0.3 to GEL 0.5 for metered residential customers and ii) from GEL 4.4 to GEL 6.5 for legal entities. The tariff increase translates into a 38% growth in allowed water revenues in the regulatory period effective from 1 January 2021. The regulatory return on investment (WACC), based on the publicly available market data and inputs, was set at 14.98% for the new regulatory period (down from 15.99%).

4Q20 operating expenses were up 14.7% y-o-y to GEL 18.1 million (up 1.1% y-o-y in FY20) primarily reflecting higher electricity and transmission costs associated with the increased electricity purchases in 4Q20. As a result, EBITDA amounted to GEL 12.1 million in 4Q20 and GEL 62.5 million in FY20, down y-o-y by 55.5% in 4Q20 and by 34.2% in FY20. Net interest expense was up 9.5% y-o-y to GEL 9.4 million in 4Q20 and up 39.8% y-o-y to GEL 33.8 million in FY20. The increase partially reflects local currency depreciation. Further, in 2020, Water Utility optimised its leverage on the back of funds attracted from IFIs and local banks to finance capital expenditures, fully refinanced by the proceeds from US$ 250 million green bond issuance in Jul-20. The 7.75% 5-year green notes were issued by JSC Georgia Global Utilities, the holding company of GCAP's water utility business and operational renewable energy assets, and were listed on the Irish Stock Exchange. The refinancing activities resulted in GEL 10.8 million non-recurring expenses in FY20, comprising primarily fees associated with the liability management exercise. Foreign exchange losses amounted to GEL 9.0 million in 4Q20 and GEL 43.4 million in FY20, as GEL depreciated against USD and EUR by 14.3% and 25.4%, respectively, during the year. As a result, net loss was GEL 15.8 million in 4Q20 (GEL 14.3 million net profit in 4Q19) and GEL 61.1 million in FY20 (GEL 33.2 million net profit in FY19).

CASH FLOW HIGHLIGHTS

FY20 operating cash flow was down by 26.9% y-o-y to GEL 55.8 million in line with the decreased revenue. However, cash collection rates for both legal entities and households remained strong at 95%+ for FY20, further supported by Government's subsidy plan for the utility bills during the pandemic for residential customers. 4Q20 operating cash flow was up by 7.3% y-o-y and EBITDA to cash conversion rate[37] was 227%, mainly reflecting: a) the advance tariff subsidy payment by the Government for January 2021 and b) collection period of September water supply revenues to legal entities, when the lockdown and other COVID-19 restrictions were minimal. FY20 development capex was down by 24.4% to GEL 57.6 million, reflecting prudent planning of capital investments and prioritizing cash preservation during the pandemic-related uncertainty. FY20 free cash flow was GEL 4.1 million, down from GEL 15.9 million in FY19. During 2020, the water utility business distributed GEL 15 million dividend to Georgia Capital, of which, GEL 10 million was paid in 4Q20. The green bond issuance led to an increase in cash flow from financing activities, contributing to 109.1% y-o-y growth in Water Utility's cash balance to GEL 55.6 million as of 31-Dec-20.

 

 

Discussion of Insurance (P&C and Medical) Business Results

Insurance business comprises a) Property and Casualty (P&C) insurance business, owned through Aldagi and b) medical insurance business, owned through GHG. P&C insurance business is a leading player in the local insurance market with a 28% market share in property and casualty insurance based on gross premiums as of 30-Sep-20. P&C also offers a variety of non-property and casualty products such as life insurance. GHG is the one the country's largest private medical insurers, with a 25.5% market share based on 3Q20 net insurance premiums. GHG offers a variety of medical insurance products primarily to Georgian corporate and state entities and also to retail clients. The medical insurance business plays a significant feeder role for GHG's polyclinics, pharmacies and hospitals. Following the GHG de-listing and the buy-out of the 29.4% minority stake in 3Q20, GCAP owns 100% in the insurance business.

 

4Q20 & FY20 performance (GEL '000), Insurance (P&C and Medical)[38]

2020 numbers are unaudited
INCOME STATEMENT HIGHLIGHTS	4Q20	4Q19	Change	FY20	FY19	Change
Earned premiums, net	37,189	38,190	-2.6%	141,614	150,698	-6.0%
Of which, P&C Insurance	19,168	18,633	2.9%	72,128	75,340	-4.3%
Of which, Medical Insurance	18,021	19,557	-7.9%	69,486	75,358	-7.8%
Net underwriting profit	13,516	9,877	36.8%	47,368	43,065	10.0%
Of which, P&C Insurance	8,980	7,546	19.0%	31,242	31,817	-1.8%
Of which, Medical Insurance	4,536	2,331	94.6%	16,126	11,248	43.4%
Net profit	7,279	5,461	33.3%	23,426	22,729	3.1%
Of which, P&C Insurance	4,970	4,845	2.6%	17,002	18,326	-7.2%
Of which, Medical Insurance	2,309	616	NMF	6,424	4,403	45.9%
CASH FLOW HIGHLIGHTS
Net cash flows from operating activities	5,901	1,595	NMF	30,959	29,868	3.7%
Of which, P&C Insurance	965	(3,137)	NMF	17,912	19,524	-8.3%
Of which, Medical Insurance	4,936	4,732	4.3%	13,047	10,344	26.1%
Free cash flow	5,309	1,244	NMF	31,617	27,783	13.8%
Of which, P&C Insurance	571	(3,410)	NMF	15,963	17,553	-9.1%
Of which, Medical Insurance	4,738	4,654	1.8%	15,654	10,230	53.0%
BALANCE SHEET HIGHLIGHTS	31-Dec-20	30-Sep-20	Change	31-Dec-19	Change
Total assets	257,887	302,885	-14.9%	279,848	-7.8%
Of which, P&C Insurance	176,479	215,283	-18.0%	200,273	-11.9%
Of which, Medical Insurance	81,408	87,602	-7.1%	79,575	2.3%
Total equity	101,507	100,143	1.4%	89,491	13.4%
Of which, P&C Insurance	69,443	69,413	NMF	62,611	10.9%
Of which, Medical Insurance	32,064	30,730	4.3%	26,880	19.3%

TOTAL INSURANCE BUSINESS HIGHLIGHTS

P&C and medical insurance have a broadly equal share in total revenues, while P&C had a 68% share in total net profit in 4Q20 (73% in FY20). The loss ratio decreased significantly in 2020 translating into an improved combined ratio (down 9.7 ppts in 4Q20 to 84.1% and down 3.1 ppts in FY20 to 86.0%). Net profit was up 33.3% y-o-y to GEL 7.3 million in 4Q20 and by 3.1% to GEL 23.4 million in FY20, y-o-y. As a result, ROAE was 28.3% in 4Q20 (24.2% in 4Q19) and 23.8% in FY20 (26.6% in FY19).

 

Discussion of results, P&C Insurance

KEY POINTS / VALUATION DRIVERS

Ø 4Q20 combined ratio down 7.8 ppts to 79.9% (down 0.6 ppts to 81.5% in FY20)

Ø Net profit up by 2.6% y-o-y in 4Q20 (down 7.2% y-o-y in FY20)

Ø GEL 10.0 million dividend paid in FY20 on the back of strong cash flow generation

Ø The business successfully continued to diversify its revenue streams in FY20

INCOME STATEMENT HIGHLIGHTS

FY20 revenues decreased by 4.3% y-o-y to GEL 72.1 million (up 2.9% y-o-y to GEL 19.2 million in 4Q20), mainly reflecting COVID-19 impact on compulsory border third-party liability insurance line (MTPL). Due to restrictions imposed on traveling, net premiums earned from MTPL was down significantly by GEL 4.2 million y-o-y in FY20 (down by GEL 1.1 million y-o-y in 4Q20). The negative impact was partially offset by the increase in other business lines (e.g. commercial property and motor insurance). Overall, despite COVID-19 and changes in customer spending habits, net premiums written across a portfolio through direct sales channels is up by 1.3% y-o-y in FY20 and by 16.9% in 4Q20. Conversely, net premiums written from partnership agreements with local financial institutions were down by 5.8% y-o-y in FY20 (reflecting the decrease in the first three quarters of 2020 by 14.6%, 18.9% and 4.4%, respectively). The trend has reversed in 4Q20, rebounding to 18.9% y-o-y growth. At 31-Dec-20, the distribution mix in gross premiums written is as follows: various direct sales channels and brokers have majority share of 74% (66% in FY19), followed by partnership agreements with financial institutions of 24% (27% in FY19) and MTPL channels of 2% (7% in FY19).

P&C Insurance's key performance ratios for FY20 and 4Q20 are as noted below:

Key Ratios, unaudited	4Q20	4Q19	Change	FY20	FY19	Change
Combined ratio	79.9%	87.7%	-7.8 ppts	81.5%	82.1%	-0.6 ppts
Expense ratio	38.5%	42.3%	-3.8 ppts	37.6%	40.6%	-3.0 ppts
Loss ratio	41.5%	45.5%	-4.0 ppts	44.0%	41.6%	2.4 ppts
ROAE	27.9%	30.5%	-2.6 ppts	24.8%	30.4%	-5.6 ppts

The 2.4 ppts y-o-y increase in the FY20 loss ratio reflects increased domestic tourism and thus, higher mobility in the second half of the year, as well as the increased number of claims in credit life insurance (10% of life claims incurred during FY20 is COVID-19 related). This was partially offset by the decreased claims in property, liability and other insurance business lines, driving 4.0 ppts y-o-y decrease in 4Q20 loss ratio. The 3.0 ppts y-o-y decrease in FY20 and 3.8 ppts y-o-y decrease in 4Q20 expense ratio reflect lower operating expenses due to cost-saving initiatives as well as a decline in the average commission rate. As a result, Aldagi's net profit was down by 7.2% to GEL 17.0 million in FY20 (up by 9.4%, when normalized for the absence of GEL 2.8 million investment income recorded in 2019) and up by 2.6% y-o-y to GEL 5.0 million in 4Q20 (up by 80.1%, when normalised for the absence of GEL 2.1 million investment income recorded in 4Q19). The ROAE was 24.8% in FY20 and 27.9% in 4Q20.

BALANCE SHEET AND CASH FLOW HIGHLIGHTS

P&C Insurance's solvency ratio was 141% as of 31 December 2020, comfortably above the required minimum of 100%. Operating cash flow was down by 8.3% y-o-y to GEL 17.9 million mainly due to larger amount of claims paid in life and motor insurance in FY20. In 4Q20, operating cash flow was up y-o-y by GEL 4.1 million from negative GEL 3.1 million due to the time gap between reimbursement of a large property claim by the reinsurer during 9M19 and settlement of the underlying claim in 4Q19. The business paid GEL 10 million dividend in FY20.

Discussion of results, Medical Insurance

KEY POINTS / KEY DRIVERS FOR VALUATION

Ø Loss ratio down 14.1 ppts y-o-y to 70.5% in 4Q20, down 8.4 ppts y-o-y to 73.0% in FY20

Ø Insurance renewal rate at 76.5% in 4Q20 (77.7% in 4Q19) and 73.4% in FY20 (77.5% in FY19)

Ø Net profit up 3.7 times y-o-y in 4Q20 to GEL 2.3 million, up 45.9% to GEL 6.4 million 

INCOME STATEMENT HIGHLIGHTS

An 8% y-o-y decline in 4Q20 and FY20 revenues reflects the decrease in the number of insured clients to c.174,000 as of 31-Dec-20 from c. 236,000 as of 31-Dec-19, mainly due to the expiry of the Ministry of Defence contract from February 2020. The reduced revenue has an immaterial impact on earnings, as the client's loss ratio was far above the business' average.

Various incentives such as the direct settlement of claims with the provider mean that, on top of its own positive contribution to GHG's profitability, the medical insurance business plays a feeder role in originating and directing patients to GHG's healthcare facilities, mainly to polyclinics and to pharmacies. The direct settlement improves claims retention rates within GHG.

Claims retention rates, unaudited

	4Q20	4Q19	Change	FY20	FY19	Change
Total claims retained within the GHG	35.5%	37.1%	-1.6ppts	37.3%	37.4%	-0.1ppts
Total claims retained in outpatient	41.7%	39.3%	2.4ppts	41.7%	40.2%	1.5ppts

The decrease in total claims retained within the Group is mainly due to expiry of Ministry of Defence contract, having higher retention rate at hospitals than average, while retention rates were improved at polyclinics, as shown in the table above.

In FY20, the net claims expenses were GEL 50.7 million (down 17.2% y-o-y), of which GEL 22.1 million (43.5% of the total) was inpatient, GEL 17.9 million (35.3% of total) was outpatient and GEL 10.7 million (21.2% of total) was related to drugs. The loss ratio improved by 14.1 ppts in 4Q20 y-o-y (from 84.6% to 70.5%) and by 8.4 ppts in FY20 (from 81.4% to 73.0%), reflecting the decreased traffic at hospitals and clinics due to the pandemic as well as the expiry of Ministry of Defence contract.

Salary and other employee benefits decreased by 11.8% in 4Q20, while they increased by 7.4% y-o-y to GEL 5.5 million in FY20 due to the accrual of performance based annual bonuses. The increase in impairment expense to GEL 0.5 million in 4Q20 (GEL 0.1 million in 4Q19) and GEL 2.0 million in FY20 (GEL 0.5 million in FY19) reflects a decline in receivables collection rate, mostly from travel agencies, as small businesses began to face difficulties due to the current circumstances caused by the pandemic.

As a result of the above developments, the combined ratio improved by 11.0 ppts to 88.6% for the quarter and by 5.5 ppts for the year to 90.6%. The business posted net profit of GEL 2.3 million for the quarter (up 3.7 times y-o-y) and GEL 6.4 million for the full year (up 45.9%). Net profit, adjusted for FX loss and non-recurring expenses, was GEL 2.2 million in 4Q20 (up 3.7 times y-o-y) and GEL 7.0 million in FY20 (up 58.8% y-o-y). Non-recurring expenses of GEL 0.8 million were recorded in FY20, related to GHG de-listing, of which, GEL 0.4 million relates to acceleration of share-based expenses for employees.

BALANCE SHEET AND CASH FLOW HIGHLIGHTS

Cash and cash equivalents balance was up 51.4% since 31-Dec-19 to GEL 25.1 million. Operating cash flow was up 4.3% y-o-y to GEL 4.9 million in 4Q20 and 26.1% y-o-y to GEL 13.0 million in FY20 on the back of decreased claims.

 

 

 

INVESTMENT STAGE PORTFOLIO COMPANIES

Discussion of Renewable Energy Business Results

The Renewable energy business operates three wholly-owned commissioned renewable assets: 50MW Mestiachala HPPs[39], 20MW Hydrolea HPPs and 21MW Qartli wind farm. In addition, a pipeline of up to 172MW renewable energy projects is under advanced stage of development. Following the buy-out of the 34.4% minority shareholder on 25-Feb-20, the renewable energy business is 100% owned by Georgia Capital. 

4Q20 & FY20 performance (GEL '000), Renewable Energy[40]

2020 numbers are unaudited
INCOME STATEMENT HIGHLIGHTS	4Q20	4Q19	Change	FY20	FY19	Change
Revenue	7,697	4,095	88.0%	42,592	16,171	NMF
Operating expenses	(3,173)	(1,326)	NMF	(10,565)	(3,196)	NMF
EBITDA	4,524	2,769	63.4%	32,027	12,975	NMF
EBITDA margin	58.8%	67.6%	-8.8 ppts	75.2%	80.2%	-5.0 ppts
Net (loss)/ profit	(6,098)	(2,594)	NMF	(16,320)	649	NMF
CASH FLOW HIGHLIGHTS
Cash flow from operating activities	11,143	1,046	NMF	40,176	2,784	NMF
Cash flow from/used in investing activities	27,991	(94,334)	NMF	15,866	(117,528)	NMF
Cash flow used in/from financing activities	(630)	108,483	NMF	(29,185)	140,204	NMF
BALANCE SHEET HIGHLIGHTS	31-Dec-20	30-Sep-20	Change	31-Dec-19	Change
Total assets	482,986	468,156	3.2%	439,455	9.9%
Of which, cash balance	66,820	28,221	NMF	35,253	89.5%
Total liabilities	326,252	310,634	5.0%	291,845	11.8%
Of which, borrowings	318,269	305,384	4.2%	274,367	16.0%
Total equity	156,734	157,522	-0.5%	147,610	6.2%
Total equity attributable to GCAP	157,454	158,242	-0.5%	111,113	41.7%

KEY POINTS / VALUATION DRIVERS

Ø Resilient 2020 results despite the COVID-19 outbreak, primarily reflecting strong momentum from acquisitions completed at the end of 2019 and energy price increases:

§ Qartli wind farm and Hydrolea contributed GEL 4.2 million to 4Q20 EBITDA (GEL 19.5 million in FY20)

§ Electricity sales price (USD) increase led to a 12.5% y-o-y like-for-like growth[41] in FY20 revenues

Ø Operating cash flow at GEL 11.1 million in 4Q20 (GEL 1.0 million in 4Q19) and GEL 40.2 million in FY20 (GEL 2.8 million in FY19)

Ø GEL 4.9 million dividend paid and GEL 40.7 million shareholder loan repaid in FY20

 

INCOME STATEMENT HIGHLIGHTS

The renewable energy business remained fully resilient from the COVID-19 outbreak, as up to 65% of electricity sales during 2020 were covered by long-term power purchase agreements (PPAs) with Electricity System Commercial Operator, a Government-backed entity, while the rest of generated electricity was sold to large industrial customers through direct contracts. In 2020, the average market sales price was up 34.5% y-o-y on like-for-like basis during non-PPA months (May-Aug) for Hydrolea and Mestiachala HPPs on the back of electricity market deregulation. PPAs with fixed purchase prices run throughout the whole year for the wind power plant and for eight months (from September through April) for HPPs.

4Q20 revenue was up 88.0% y-o-y to GEL 7.7 million (up by GEL 26.4 million to GEL 42.6 million in FY20), reflecting the acquisitions of Qartli wind farm and Hydrolea HPPs at the end of 4Q19:

₋     The 21MW Qartli wind farm contributed GEL 4.5 million to 4Q20 revenues on the back of 21.0 GWh electricity generation (GEL 18.5 million to FY20 with 90.8 GWh generation and an outstanding capacity factor of 50%);

₋     The 20MW Hydrolea HPPs added GEL 1.6 million to 4Q20 revenues (the fourth quarter is seasonally slow for HPPs). FY20 revenue was GEL 7.1 million, having been negatively affected by almost 7 months' shutdown of the 9MW Akhmeta HPP in 2020 for planned rehabilitation works until mid-July;

₋     4Q20 revenue from the Mestiachala HPPs was GEL 1.6 million. FY20 revenues at GEL 16.8 million derive from GEL 12.6 million electricity sales from the 30MW Mestiachala HPP and GEL 4.2 million business interruption insurance reimbursement for the 20MW Mestiachala HPP, where the restoration process is still ongoing.

The increase in operating expenses in 4Q20 and FY20 reflects the addition of expenses as a result of acquisitions of Qartli wind farm and Hydrolea HPPs. 4Q20 EBITDA was up 63.4% y-o-y to GEL 4.5 million (up almost 3x to GEL 32.0 million in FY20). EBITDA margin was 58.8% in 4Q20 and 75.2% in FY20. The fourth quarter is generally characterised by lower EBITDA margins, as HPPs' generation levels peak seasonally during the second and third quarters of the year.

Borrowings increased by 16.0% in FY20, of which 14.3% increase was due to GEL depreciation. However, electricity sales are fully in US dollars, creating a natural cash flow hedge against GEL depreciation. Electricity sales price (USD) increase led to a 12.5% y-o-y like-for-like growth[42] in FY20 revenues, like-for-like growth was 23.4% based on increase in electricity sales price (GEL). The business recorded GEL 6.5 million net interest expense in 4Q20 (GEL 23.4 million in FY20). In addition, GEL 10.6 million non-recurring expenses were incurred in 2020 for the liability management exercise in connection with US$ 250 million green bond issuance in Jul-20, as described on page 15 of this report. As a result, the net loss amounted to GEL 6.1 million in 4Q20 and GEL 16.3 million in FY20.

CASH FLOW HIGHLIGHTS

The acquisitions and increased electricity sales prices led to improved operating cash flow generation, up from GEL 1.0 million y-o-y in 4Q20 to GEL 11.1 million (up from GEL 2.8 million y-o-y to GEL 40.2 million in FY20). FY20 operating cash flow includes a GEL 11.3 million insurance reimbursement for business interruption, fully compensating the foregone 2019 revenues of the 50MW Mestiachala HPPs and 2020 Jan-July revenues of 20MW Mestiachala HPP. Additionally, the insurance company reimbursed GEL 40.9 million for property damage of the 50MW Mestiachala HPPs in FY20, of which GEL 30.4 million was received in 4Q20. As a result, cash inflow from investing activities was GEL 15.9 million in FY20 and the cash balance increased by GEL 38.6 million q-o-q in 4Q20 (up by GEL 31.6 million in FY20). In 2020, the renewable energy business distributed GEL 4.9 million in dividends to Georgia Capital and repaid the shareholder loans in the amount of GEL 40.7 million.

 

Discussion of Education Business Results

Our education business currently combines majority stakes in four leading private schools, acquired in 2H19: British-Georgian Academy and British International School of Tbilisi (70% stake), the leading schools in the premium segment; Buckswood International School (80% stake), well-positioned in the mid-level segment and Green School (80%-90% ownership[43]), a leading player in the affordable education segment. 

4Q20 & FY20 performance (GEL '000), Education[44]

2020 numbers are unaudited
INCOME STATEMENT HIGHLIGHTS	4Q20	4Q19	Change	FY20	FY19	Change
Revenue	8,683	8,246	5.3%	25,794	24,575	5.0%
Operating expenses	(4,566)	(5,418)	-15.7%	(17,446)	(17,310)	0.8%
EBITDA	4,117	2,828	45.6%	8,348	7,265	14.9%
EBITDA Margin	47.4%	34.3%	+13.1ppts	32.4%	29.6%	+2.8ppts
Net profit	4,186	2,104	99.0%	3,148	2,312	36.2%
CASH FLOW HIGHLIGHTS
Net cash flows from operating activities	(208)	973	NMF	7,877	9,591	-17.9%
Net cash flows from investing activities	(2,077)	(1,629)	27.5%	(7,129)	(8,925)	-20.1%
Net cash flows from financing activities	(641)	(263)	NMF	78	1,882	-95.9%
BALANCE SHEET HIGHLIGHTS	31-Dec-20	30-Sep-20	Change	31-Dec-19	Change
Total assets	110,541	112,742	-2.0%	105,158	5.1%
Of which, cash	6,399	9,158	-30.1%	5,133	24.7%
Total liabilities	53,396	57,432	-7.0%	48,394	10.3%
Of which, borrowings	24,947	24,268	2.8%	19,809	25.9%
Total equity	57,145	55,310	3.3%	56,764	0.7%
Total equity attributable to GCAP	53,553	52,747	1.5%	55,494	-3.5%

 KEY POINTS / VALUATION DRIVERS

Ø Solid y-o-y growth in 4Q20 and FY20 revenues and EBITDA, despite COVID-19 implications  

Ø Strong intakes with c. 86% utilisation rate for 1^st graders in 2020-2021 academic year, total capacity utilisation at 89.5%

Ø Significant cost optimisation initiatives and distance learning translating into an outstanding improvement in EBITDA margin, up by 13.1 ppts y-o-y to 47.4% in 4Q20 and up by 2.8 ppts y-o-y to 32.4% in FY20

Ø Cash collection rates largely at 2019 levels, translating into operating cash flow of GEL 7.9mln in FY20

INCOME STATEMENT HIGHLIGHTS

In light of the COVID-19, the schools were providing distance learning from March 1^st for the most part of 2020. During the distance learning period schools offered 15-25% discounts for tuition fees and roll-over of fees for transportation/catering services. Due to the pandemic, summer schools were largely cancelled and FY20 revenues from additional services (like catering and transportation) decreased by 24.8% y-o-y to GEL 0.8 million. Given the improved epidemiological developments in Georgia, the schools in Tbilisi were reopened from 15 February 2021.

However, despite COVID-19 implications, the education business continued to deliver growing revenues in 2020 (up 5.3% in 4Q20 and 5.0% in FY20 y-o-y), reflecting both 5.6% y-o-y increase in FY20 average tuition fee per learner and strong intakes. Tuition fees usually increase via contract renewals in line with grade level progression for existing learners, while announced intake fees for new enrolments are also subject to upward revisions usually every 1-3 years depending on the segment. The intakes remained strong for all grades other than Preschool and Kindergarten, with c. 86% utilisation rate for 1^st graders in 2020-2021 academic year. The COVID-19 lockdown and distance learning does not allow schools to provide most of the services offered to Kindergarten and Preschool learners, however, generally these learners pay the lowest fee. Overall total number of learners were down 2.6% y-o-y to 2,516 learners at 31-Dec-20, while the total number of learners adjusted to exclude Preschool and Kindergarten learners was up 1.9% y-o-y to 2,433 learners at 31-Dec-20. The combined school capacity utilization also remained largely at last year's level with minor decrease of 2.4 ppts y-o-y to 89.5%, as follows: down to 92.6% and 741 learners in BGA & BIST (95.3% and 762 learners as of 31-Dec-19); flat at 90.0% and 684 learners in Buckswood; down to 87.3% and 1,091 learners in Green School (90.9% and 1,136 learners as of 31-Dec-19).

The growing revenues coupled with significant cost optimisation initiatives in light of COVID-19 and distance learning, resulted in increased EBITDA, up 45.6% to GEL 4.1 million in 4Q20 and up 14.9% to GEL 8.3 million in FY20, y-o-y. Similarly, EBITDA margin improved y-o-y by 13.1 ppts to 47.4% in 4Q20 and by 2.8 ppts to 32.4% in FY20. Net income was GEL 4.2 million in 4Q20 and GEL 3.1 million in FY20, reflecting foreign currency exchange losses due to local currency depreciation.

CASH FLOW HIGHLIGHTS

Cash collection was negatively affected by reduced revenues from summer schools and discounts & roll-overs offered for certain services, resulting in a 17.9% y-o-y decrease in operating cash flow to GEL 7.9 million in FY20. Overall, the combined cash collection rate for 2020-2021 tuition fees stood at 74.0% (83.8% at 31-Dec-19), which was in line with the schools' cash collection policies.

 

Discussion of Other Portfolio Results

The five businesses in our "other" private portfolio are Housing Development, Hospitality and Commercial Real Estate, Beverages, Auto Service and Digital Services. They had a combined value of GEL 214.9 million at 31-Dec-20, which represented only 7.4% of our total portfolio.

 

4Q20 & 2020 aggregated performance highlights (GEL '000), Other Portfolio

2020 numbers are unaudited	4Q20	4Q19	Change	2020	2019	Change
Revenue	93,129	99,421	-6.3%	321,346	280,611	14.5%
EBITDA	13,045	2,827	NMF	32,053	4,608	NMF
Net cash flows from operating activities	16,245	(4,514)	NMF	74,525	(13,932)	NMF

 

Aggregated EBITDA and operating cash flow generation improved significantly in both 4Q20 and FY20, mainly reflecting the outstanding performance of the wine and auto services businesses. The growth was further supported by increased earnings in Housing Development, supported by the increased number of on-going projects in 2020 and improved performance in the beer business benefiting from the full scale launch of new brands since 2H19.

The wine business demonstrated an outstanding performance in 4Q20, increasing the number of bottles sold by 45.1% y-o-y. As a result, the business posted an all-time high quarterly EBITDA of GEL 8.2 million in 4Q20 (up 60.3% y-o-y) and FY20 EBITDA of GEL 11.0 million (up 26.5% y-o-y). Net cash flow from operating activities was up from negative GEL 0.5 million in 4Q19 to GEL 5.2 million in 4Q20 in the wine business (up more than four times y-o-y in FY20 to GEL 11.5 million).

Similarly, the performance was robust in the auto services business, with 4Q20 EBITDA increasing almost three times y-o-y to GEL 1.9 million (more than doubled to GEL 5.0 million in FY20). Net cash flow from operating activities tripled y-o-y to GEL 1.5 million in 4Q20 in the auto services business (up from negative GEL 0.1 million in FY19 to GEL 1.7 million in FY20).

 

 

 

 

RECONCILIATION OF ADJUSTED INCOME STATEMENT TO IFRS INCOME STATEMENT

The table below reconciles the adjusted income statement to the IFRS income statement. Adjustments to reconcile adjusted income statement with IFRS income statement mainly relate to eliminations of income, expense and certain equity movement items recognised at JSC Georgia Capital, which are subsumed within gross investment loss in IFRS income statement of Georgia Capital PLC.

		4Q20, unaudited			FY20, unaudited
GEL '000, unless otherwise noted	Adjusted IFRS income statement		Adjustment	IFRS  income statement	Adjusted IFRS income statement	Adjustment	IFRS  income statement
Dividend income	14,972		(14,972)	-	29,870	(29,870)	-
Interest income	4,307		(4,307)	-	20,957	(20,957)	-
Realized / unrealized (loss)/ gain on liquid funds	1,119		(1,119)	-	(2,984)	2,984	-
Interest expense	(16,537)		16,537	-	(62,478)	62,478	-
Gross operating (loss)/income	3,861		(3,861)	-	(14,635)	14,635	-
Operating expenses	(9,109)		6,944	(2,165)	(32,136)	24,187	(7,949)
GCAP net operating (loss)/income	(5,248)		3,083	(2,165)	(46,771)	38,822	(7,949)
Total investment return / gross investment loss	495,157		(13,372)	481,785	449,615	(110,441)	339,174
(Loss)/Income before foreign exchange movements and non-recurring expenses	489,909		(10,289)	479,620	402,844	(71,619)	331,225
Net foreign currency loss	(14,421)		14,702	281	(90,943)	90,052	(891)
Non-recurring expenses	(166)		166	-	(3,389)	3,389	-
Net (loss)/Income	475,322		4,579	479,901	308,512	21,822	330,334

 

DETAILED FINANCIAL INFORMATION

IFRS CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME

OF GEORGIA CAPITAL PLC (2020)[45]

GEL '000, unless otherwise noted	2020, unaudited
Gains on investments at fair value	339,174
Gross investment profit	339,174
Administrative expenses	(5,430)
Salaries and other employee benefits	(2,519)
Profit before foreign exchange	331,225
Net foreign currency loss	(891)
Profit before income taxes	330,334
Income tax	-
Profit for the year	330,334
Other comprehensive income	-
Total comprehensive income for the year	330,334
Earnings per share:
- basic	8.2302
- diluted	8.1966

 

 

 

 

IFRS CONSOLIDATED INCOME STATEMENT (2019)

GEL '000, unless otherwise noted	2019 Audited
Revenue	1,473,437
Cost of sales	(883,024)
Gross profit	590,413
Salaries and other employee benefits	(177,000)
Administrative expenses	(116,911)
Other operating expenses	(11,464)
Expected credit loss on financial assets	(11,474)
Impairment charge on insurance premium receivables, other assets and provisions	(1,078)
	(317,927)
EBITDA	272,486
Share in profit of associates	357
Dividend income	24,953
Depreciation and amortisation	(110,075)
Net foreign currency loss	(41,663)
Net gains from investment securities measured at FVPL	1,654
Net realised gains from investment securities measured at FVOCI	1,187
Interest income	30,672
Interest expense	(150,370)
Net operating income before non-recurring items	29,201
Net non-recurring items	(9,130)
Gain from change in investment entity status	588,828
Income before income tax expense	608,899
Income tax expense	(4,633)
Profit for the year	604,266
Total profit attributable to:
- shareholders of Georgia Capital PLC	569,262
- non-controlling interests	35,004
	604,266
Earnings per share:
- basic	16.4478
- diluted	16.0932

 

IFRS CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (2019)

GEL '000, unless otherwise noted	2019 Audited
Profit for the year	604,266
Other comprehensive income
Other comprehensive loss to be reclassified to profit or loss in subsequent periods:
Income from currency translation differences	9,964
Changes in the fair value of debt instruments at FVOCI	2,694
Realised gain on financial assets measured at FVOCI reclassified to the consolidated income statement	(1,187)
Change in allowance for expected credit losses on investments in debt instruments measured at FVOCI	(172)
Reclassification of other reserves to PL due to Change in investment entity status	(26,866)
Net other comprehensive loss to be reclassified to profit or loss in subsequent periods	(15,567)
Other comprehensive income not to be reclassified to profit or loss in subsequent periods:
Revaluation of property and equipment	3,474
Changes in fair value of equity instruments designated at FVOCI	140,441
Reclassification of other reserves to retained earnings due to Change in investment entity status	108,265
Net other comprehensive income not to be reclassified to profit or loss in subsequent periods	252,180
Other comprehensive income for the year, net of tax	236,613
Total comprehensive income for the year	840,879
Total comprehensive income attributable to:
- shareholders of Georgia Capital PLC	804,036
- non-controlling interests	36,843
	840,879

 

 

IFRS CONSOLIDATED STATEMENT OF FINANCIAL POSITION OF GEORGIA CAPITAL PLC[46]

GEL '000, unless otherwise noted	31 December 2020 Unaudited	31 December 2019 Audited
Assets
Cash and cash equivalents	855	1,243
Prepayments	426	234
Equity investments at fair value	2,213,290	1,758,197
Total assets	2,214,571	1,759,674
Liabilities
Other liabilities	2,279	7,653
Total liabilities	2,279	7,653
Equity
Share capital	1,574	1,320
Additional paid-in capital and merger reserve	238,311	108,863
Retained earnings	1,972,407	1,641,838
Total equity	2,212,292	1,752,021
Total liabilities and equity	2,214,571	1,759,674

 

IFRS CONSOLIDATED STATEMENT OF CASH FLOWS OF GEORGIA CAPITAL PLC

GEL '000, unless otherwise noted	2020* Unaudited	2019* Audited
Cash flows from operating activities
Revenue received	-	1,386,928
Cost of goods sold paid	-	(896,818)
Interest income received	-	23,363
Salaries and other employee benefits paid	(2,109)	(150,122)
General, administrative and operating expenses paid	(4,966)	(111,162)
Net other income received	-	7,207
Net change in operating assets and liabilities	-	977
Net cash flows (used in) / from operating activities before income tax	(7,075)	260,373
Income tax paid	-	(4,082)
Net Cash flow (used in) / from operating activities	(7,075)	256,291
Cash flows used in investing activities
Capital redemption from subsidiary	21,180	-
Net placement of amounts due from credit institutions	-	(16,240)
Loans repaid	-	114,654
Acquisition of subsidiaries, net of cash acquired	-	(160,348)
Repayment of remaining holdback amounts from previous year acquisitions	-	(5,876)
Purchase of marketable securities	-	(81,970)
Proceeds from sale and redemption of marketable securities	-	125,534
Purchase of investments in associates	-	(10,822)
Proceeds from sale of investment properties	-	860
Purchase and construction of investment properties	-	(13,430)
Proceeds from sale of property and equipment and intangible assets	-	11,162
Purchase of property and equipment	-	(283,402)
Purchase of intangible assets	-	(28,740)
Dividends received	-	24,953
Change in investment entity status	-	(248,735)
Cash flows from / (used in) investing activities	21,180	(572,400)
Cash flows from financing activities
Proceeds from borrowings	-	660,400
Repayment of borrowings	-	(416,682)
Proceeds from debt securities issued	-	247,053
Redemption and buyback of debt securities issued	-	(106,713)
Other purchases of treasury shares	-	(75,428)
Dividends paid	-	(11,405)
Interest paid	-	(148,790)
Contributions under share-based payment plan	(317)	(60,461)
Increase in share capital of subsidiaries	-	6,215
Purchase of additional interest in existing subsidiaries	-	(1,615)
Transaction costs incurred in relation to share issuance	(14,215)	(1,106)
Cash payments for principal portion of lease liability	-	(21,087)
Cash payments for interest portion of the lease liability	-	(6,665)
Net cash (used in) / from financing activities	(14,532)	63,716
Effect of exchange rates changes on cash and cash equivalents	39	(3,294)
Effect of change in expected credit losses for cash and cash equivalents	-	-
Net decrease in cash and cash equivalents	(388)	(255,687)
Cash and cash equivalents, beginning of the year	1,243	256,930
Cash and cash equivalents, end of the year	855	1,243

* Figures for the year ended 31 December 2019 are consolidated, while figures for the year ended 31 December 2020 include Georgia Capital standalone figures.

IFRS CONSOLIDATED STATEMENT OF CHANGES IN EQUITY OF GEORGIA CAPITAL PLC

Unaudited, GEL '000, unless otherwise noted	Share capital	Additional paid-in capital and merger reserve	Retained earnings	Total
31 December 2019	1,320	108,863	1,641,838	1,752,021
Profit for the year	-	-	330,334	330,334
Total comprehensive profit for the year	-	-	330,334	330,334
Increase in equity arising from share-based payments	-	-	552	552
Issue of share capital	254	138,011	-	138,265
Transaction costs recognized directly in equity	-	(8,563)	-	(8,563)
Purchase of treasury shares	-	-	(317)	(317)
31 December 2020	1,574	238,311	1,972,407	2,212,292

 

SELECTED EXPLANATORY NOTES TO THE IFRS FINANCIAL STATEMENTS OF GEORGIA CAPITAL PLC (UNAUDITED)

GOING CONCERN

The Board of Directors of Georgia Capital has made an assessment of the Group's and Company's ability to continue as a going concern and is satisfied that it has the resources to continue in business for a period of at least 12 months from the date of approval of the financial statements, i.e. the period ending 31 March 2022. Furthermore, management is not aware of any material uncertainties that may cast significant doubt upon the Group's and Company's ability to continue as a going concern for the foreseeable future. Therefore, the separate and consolidated financial statements continue to be prepared on a going concern basis.

The Directors have made an assessment of the appropriateness of the going concern basis of preparation and reviewed Georgia Capital liquidity outlook for the period ending 31 March 2022, taking into account the impact of the COVID-19 pandemic and considered any potential concerns with respect to the liquidity and recoverability of the Group's assets as set out in the financial statements. As a response to the COVID-19 uncertainties, Georgia Capital continues to remain  focused on limiting capital allocations, optimizing operating expenses and cash accumulation and preservation.

The main source of cash inflow for GCAP PLC is capital redemption from JSC GCAP, which itself has enough assets to support the liquidity needs of the parent company as well. As at 31 December 2020, JSC GCAP holds cash in the amount of GEL 117,026, amounts due from credit institutions in the amount of GEL 42,655 and marketable debt securities in the amount of GEL 13,416, which are considered to be highly liquid, as all of them represent listed debt instruments on international and local markets. Liquidity needs of the holding companies (which includes JSC GCAP as well) during the Going Concern review period mainly comprises of coupon payments on JSC GCAP Eurobonds and operating costs of running the holding companies. The liquidity outlook also assumes dividend income from the defensive businesses of the group (healthcare, pharmacy, renewable business, water utility and insurance) and small capital allocations in Investment stage companies (Renewable Energy and Education). Management have performed a further assessment which demonstrates that, even in a stressed scenario which assumes no dividend inflows and postponement of the loan repayments from the portfolio businesses that have been most significantly negatively affected by the COVID-19 whilst retaining forecast capital allocations, the existing cash and highly liquid debt and equity investment securities will be sufficient to cover the expected cash outflows of the holding companies for the Going Concern review period. Further, Georgia Capital does not have any formal capital or debt commitments to its portfolio companies, with the  exception of an 18 million euro financial guarantee issued to a portfolio company owned by JSC GCAP, where the management has assessed the probability of guarantee exercise as remote and has included it in the overall assessment accordingly. Finally, Georgia Capital does not have a primary mandate to deploy funds or divest assets within a specific time frame.

Georgia has, so far, managed to effectively deal with the COVID-19 pandemic. The Georgian Government has taken significant actions at the early stage of COVID-19 outbreak. A large part of Georgia Capital's portfolio is concentrated across defensive countercyclical sectors: the water utility and healthcare and pharmacy distribution businesses. Georgia Capital has adequate liquidity position as at 31 December 2020. On 30 July 2020, GGU (the holding company of water utility and renewable energy businesses) issued USD 250 million 7.75% 5-year green notes, improving the financial flexibility of GGU, allowing this business to repay its loans to JSC Georgia Capital and significantly enhancing liquidity profile of the group.

The management is also satisfied that Georgia Capital's liquidity forecast is comprehensive considering the novel coronavirus risk. Due to COVID-19 related uncertainties, which may affect portfolio businesses ability to distribute cash to Georgia Capital (either in the form of dividend distribution or repayment of loans from JSC GCAP), management of Georgia Capital is focused on minimizing capital allocations, applying operating expense optimization plans and preserving cash, all of which are incorporated into the forecasts, which represents the basis for going concern conclusion.

 

FAIR VALUE MEASUREMENTS

Valuation techniques

The following is a description of the determination of fair value for financial instruments which are recorded at fair value using valuation techniques. These incorporate the Group's estimate of assumptions that a market participant would make when valuing the instruments.

Assets for which fair value approximates carrying value

For financial assets and financial liabilities that are liquid or have a short term maturity (less than three months), it is assumed that the carrying amounts approximate to their fair value. This assumption is also applied to demand deposits, savings accounts without a specific maturity and variable rate financial instruments.

Fixed rate financial instruments

The fair value of fixed rate financial assets and liabilities carried at amortised cost are estimated by comparing market interest rates when they were first recognised with current market rates offered for similar financial instruments. The estimated fair value of fixed interest bearing deposits is based on discounted cash flows using prevailing money-market interest rates for debts with similar credit risk and maturity.

Investment in subsidiaries

Equity investments at fair value include investment in subsidiary at fair value through profit or loss representing 100% interest of JSC Georgia Capital. Georgia Capital PLC holds a single investment in JSC Georgia Capital (an investment entity on its own), which holds a portfolio of investments, both meet the definition of investment entity and Georgia Capital PLC measures its investment in JSC Georgia Capital at fair value through profit or loss. Investments in investment entity subsidiaries and loans issued are accounted for as financial instruments at fair value through profit and loss in accordance with IFRS 9. Debt securities owned are measured at fair value through other comprehensive income. We determine that, in the ordinary course of business, the net asset value of investment entity subsidiaries is considered to be the most appropriate to determine fair value. JSC Georgia Capital's net asset value as of 31 December 2020 and 31 December 2019 is determined  as follows:

	31 December 2020 Unaudited		31 December 2019 Audited
Assets
Cash and cash equivalents	117,026		117,215
Amounts due from credit institutions	42,655		-
Marketable securities	13,416		62,493
Equity investments at fair value	2,907,688		2,251,465
Of which listed investments	531,558		1,027,814
GHG*	-		430,079
BOG**	531,558		597,735
Of which private investments:	2,376,130		1,223,651
Large portfolio companies	1,858,237		648,893
Healthcare services	571,656		-
Retail (Pharmacy)	552,745		-
Water utility	471,148		483,970
P&C insurance	197,806		164,923
Medical insurance	64,882		-
Investment stage portfolio companies	302,964		163,116
Renewable energy	209,902		106,800
Education	93,062		56,316
Other portfolio companies	214,969		411,642
Loans issued	108,983		151,884
Other assets	7,276		8,782
Total assets	3,197,044		2,591,839
Liabilities
Debt securities issued	980,932		825,952
Other liabilities	2,822		7,690
Total liabilities	983,754		833,642
Net Asset Value	2,213,290		1,758,197

 

*Delisted and transferred to private portfolio in August 2020

** In 2019 the group recognized dividend income in the amount of GEL 24,953  from investment in Bank of Georgia Group PLC.

 

In measuring fair values of JSC Georgia Capital's investments, following valuation methodology is applied:

Equity Investments in Listed Portfolio Companies

Equity instruments listed on an active market are valued at the price within the bid/ask spread, that is most representative of fair value at the reporting date, which usually represents the closing bid price. The instruments are included within Level 1 of the hierarchy in JSC GCAP financial statements.

Equity Investments in Private Portfolio Companies

Large portfolio companies - An independent third-party valuation firm is engaged to assess fair value ranges of large private portfolio companies at the reporting date starting from 2020 (fair value assessment was performed internally as at 31 December 2019). The independent valuation company has extensive relevant industry and emerging markets experience. Valuation is performed by applying several valuation methods that are weighted to derive fair value range, with income approach being more heavily weighted than market approach. Management selects most appropriate point in the provided fair value range at the reporting date.

Investment stage and other portfolio companies - fair value assessment is performed internally as described below.

Equity investments in private portfolio companies are valued by applying an appropriate valuation method, which makes maximum use of market-based public information, is consistent with valuation methods generally used by market participants and is applied consistently from period to period, unless a change in valuation technique would result in more reliable estimation of fair value.

The value of an unquoted equity investment is generally crystallised through the sale or flotation of the entire business. Therefore, the estimation of fair value is based on the assumed realisation of the entire enterprise at the reporting date. Recognition is given to the uncertainties inherent in estimating the fair value of unquoted companies and appropriate caution is applied in exercising judgments and in making the necessary estimates.

Fair value of equity investment is determined using one of the valuation methods described below:

Listed Peer Group Multiples

This methodology involves the application of a listed peer group earnings multiple to the earnings of the business and is appropriate for investments in established businesses for which the company can determine a group of listed companies with similar characteristics.

The earnings multiple used in valuation is determined by reference to listed peer group multiples appropriate for the period of earnings calculation for the investment being valued. The Group identifies peer group for each equity investment taking into consideration points of similarity with the investment such as industry, business model, size of the company, economic and regulatory factors, growth prospects (higher growth rate) and risk profiles. Some peer-group companies' multiples may be more heavily weighted during valuation if their characteristics are closer to those of the company being valued than others.

As a rule of thumb, last 12-month earnings will be used for the purposes of valuation as a generally accepted method. Earnings are adjusted where appropriate for exceptional, one-off or non-recurring items.

a.     Valuation based on enterprise value

Fair value of equity investments in private companies can be determined as their enterprise value less net financial debt (gross face value of debt less cash) appearing in the most recent Financial Statements.

Enterprise value is obtained by multiplying measures of a company's earnings by listed peer group multiple (EV/EBITDA) for the appropriate period. The measures of earnings generally used in the calculation is recurring EBITDA for the last 12 months (LTM EBITDA). In exceptional cases, where EBITDA is negative, peer EV/Sales (enterprise value to sales) multiple can be applied to last 12-month recurring/adjusted sales revenue of the business (LTM sales) to estimate enterprise value.

Equity Investments in Private Portfolio Companies (continued)

Once the enterprise value is estimated, the following steps are taken:

·      Net financial debt appearing in the most recent financial statements is subtracted from the enterprise value. If net debt exceeds enterprise value, the value of shareholders' equity remains at zero (assuming the debt is without recourse to Georgia Capital).

·      The resulting fair value of equity is apportioned between Georgia Capital and other shareholders of the company being valued, if applicable.

Valuation based on enterprise value using peer multiples is used for businesses within non-financial industries.

b.     Equity fair value valuation

Fair value of equity investment in companies can determined as using price to earnings (P/E) multiple of similar listed companies.

The measure of earnings used in the calculation is recurring adjusted net income (net income adjusted for non-recurring items and forex gains/ losses) for the last 12 months (LTM net income). The resulting fair value of equity is allocated between Georgia Capital and other shareholders of the portfolio company, if any. Fair valuation of equity using peer multiples can be used for businesses within financial sector (e.g. insurance companies). Under the discounted cash flow analysis unobservable inputs are used, such as estimates of probable future cash flows and an internally-developed discounting rate of return.

Discounted cash flow

Under the discounted cash flow (DCF) valuation method, fair value is estimated by deriving the present value of the business using reasonable assumptions of expected future cash flows and the terminal value, and the appropriate risk-adjusted discount rate that quantifies the risk inherent to the business. The discount rate is estimated with reference to the market risk-free rate, a risk adjusted premium and information specific to the business or market sector.

Net Asset Value

The net assets methodology (NAV) involves estimating fair value of equity investment in a private portfolio company based on its book value at reporting date. This method is appropriate for businesses whose value derives mainly from the underlying value of its assets and where such assets are already carried at their fair values (fair values determined by professional third-party valuation companies) on the balance sheet.

Price of recent investment

The price of a recent investment resulting from an orderly transaction, generally represents fair value as of the transaction date. At subsequent measurement dates, the price of a recent investment may be an appropriate starting point for estimating fair value. However, adequate consideration is given to the current facts and circumstances to assess at each measurement date whether changes or events subsequent to the relevant transaction imply a change in the investment's fair value.

Validation

Fair value of investments estimated using one of the valuation methods described above is cross-checked using several other valuation methods as follows:

·      Listed peer group multiples - peer multiples such as P/E, P/B (price to book) and dividend yield are applied to respective metrics of the investment being valued depending on the industry of the company.  The Company develops fair value range based on these techniques and analyse whether fair value estimated above falls within this range.

·      Discounted cash flow (DCF) - The discounted cash flow valuation method is used to determine fair value of equity investment. Based on DCF, the Company might make upward or downward adjustment to the value of valuation target as derived from primary valuation method.  If fair value estimated using discounted cash flow analysis significantly differs from the fair value estimate derived using primary valuation method, the difference is examined thoroughly, and judgement is applied in estimating fair value at the measurement date.

Description of significant unobservable inputs to level 3 valuations[47]

The approach to valuations as of 31 December 2020 was consistent with the Group's valuation process and policy. Key focus of the valuations at 31 December 2020 was an assessment of the impact of the COVID-19 pandemic on each portfolio company. Management continues to monitor the impact that the COVID-19 pandemic has on the valuation of portfolio companies.

The following tables show descriptions of significant unobservable inputs to level 3 valuations of investments in subsidiaries:

31 December 2020 (unaudited)
Description	Valuation technique	Unobservable input	Range [selected input]	Fair value
Loans Issued	DCF	Discount rate	9%-16%	108,983
Equity investments at fair value
Large portfolio				1,858,237
Healthcare services	DCF, EV/EBITDA	EV/EBITDA multiple	7.4x-65.8x [13.2x]	571,656
Retail (Pharmacy)	DCF, EV/EBITDA	EV/EBITDA multiple	7.2x-18.4x [9.1x]	552,745
Water utility	DCF, EV/EBITDA	EV/EBITDA multiple	8.8x-12.4x [9.4x]	471,148
P&C insurance	DCF, P/E	P/E multiple	7.1x-18.1x [11.6x]	197,806
Medical insurance	DCF, P/E	P/E multiple	9.6x-15.6x [10.1x]	64,882
Investment stage				302,964
Renewable energy	Sum of the parts	EV/EBITDA multiple	11.3x-21.3x [9.0x-10.5x]	209,902
Education	EV/EBITDA	EV/EBITDA multiple	7.2x-21.8x [12.5x]	93,062
Other	Sum of the parts	EV/EBITDA multiples	5.1x-19.9x [5.0x-10.0]	214,929
		EV/Sales multiple	1.2x-4.7x [2.4x]
		Cashflow probability	[90%-100%]
		NAV multiple	[0.9x]

 

Georgia Capital hired third-party valuation professionals to assess fair value of the large private portfolio companies as at 31 December 2020, including Water Utility, P&C insurance and the three businesses (Healthcare Services, Retail (Pharmacy) and Medical Insurance) that constituted GHG PLC and were transferred to the private portfolio and are valued as private companies after Georgia Healthcare Group PLC's delisting from London Stock Exchange in August 2020. Valuation is performed by applying several valuation methods that are weighted to derive fair value range, with income approach being more heavily weighted than market approach. Management selects most appropriate point in the provided fair value range at the reporting date.

The Education and Renewable businesses were valued at recent transaction price as at 31 December 2019.  Changes in the valuation methodology relating to the Education business and certain components of the Renewable business have been applied in this reporting period.  These changes reflect IPEV valuation guidelines, the passage of time since the transaction and the impact of changes made post investment. Consequently, as of 31 December 2020, the Education business is valued using an EV/EBITDA multiple, whilst the Renewables business is valued on the basis of sum of the parts (recent transaction price and EV/EBITDA multiple).

Fair value of investment property held by Hospitality and Commercial business (presented within "other" in equity investments) is estimated by independent third party valuers. Due to COVID-19 impact on real estate markets, investment property valuations are reported on the basis of 'material valuation uncertainty' as per VPS 3 and VPGA 10 of the RICS Red Book Global. Consequently, less certainty and a higher degree of caution should be attached to the valuation than would normally be the case.

In order to determine reasonably possible alternative assumptions the Group adjusted key unobservable model inputs. The Group adjusted the inputs used in valuation by increasing and decreasing them within a range which is considered by the Group to be reasonable.

If the interest rate for each individual loan issued to subsidiaries as at 31 December 2020 decreased by 20% (2019: 20%), the amount of loans issued would have decreased by GEL 1,494 or 1.4% (2019: GEL 609 or 0,5%). If the interest rates increased by 20% then loans issued would have increased by GEL 1,502 or 1.4% (2019: GEL 617 or 0.5%).

If the listed peer multiples used in the market approach to value unquoted investments as at 31 December 2020 decreased by 10% (2019: 5%), value of equity investments at fair value would decrease by GEL 117 million or 4% (2019: GEL 62 million or 8%). If the multiple increased by 10% (2019: 5%) then the equity investments at fair value would increase by GEL 117 million or 4% (2019: GEL 62 million or 8%).

If the discount rates used in the income approach to value unquoted investments decreased by 50 basis points (2019: 59 basis points), the value of equity investments at fair value would increase by GEL 91 million or 3% (2019: GEL 2 million or 4%). If the discount rates increased by 50 basis points (2019: 59 basis points) then the equity investments at fair value would decrease by GEL 87 million or 3% (GEL 2 million or 4%). If the discount rate decreased by 100 basis points, the value of equity investments at fair value would increase by GEL 192 million or 7%. If the discount rate increased by 100 basis points then the equity investments at fair value would decrease by GEL 166 million or 6%.

If the multiple used to value unquoted investments valued on NAV and recent transaction price basis (except for Hospitality and Commercial business) as at 31 December 2020 decreased by 10% (2019: 5%), value of equity investments at fair value would decrease by GEL 12 million or 0.4% (2019: GEL 21 million or 5%). If the multiple increased by 10% then the equity investments at fair value would increase by GEL 12 million or 0.4% (2019: GEL 21 million or 5%).

 

ADDITIONAL FINANCIAL INFORMATION^[48]

Revised NAV format overview since 3Q20 reporting period

The valuation methodology of the investments together with the methodology underlying the preparation of the NAV Statement is unchanged from 31 December 2019 as included in 2019 Annual Report, except that valuation assessment of our large businesses was performed by an independent valuation company, further described under the "Basis of presentation". With the completion of a recommended share exchange offer for GHG shareholders in 3Q20 and its de-listing in August, Georgia Capital acquired the 29.4% remaining equity stake in previously separately listed GHG (the "GHG Buy-out"), adding three private businesses to its private portfolio (healthcare services, retail (pharmacy) and medical insurance).

Following the GHG Buy-out, as discussed on Georgia Capital Investor Day on 12-Nov-20, we have adapted the structure of our management and internal reporting for our private portfolio businesses, and going forward for reporting purposes we are dividing those businesses into three categories: large, investment stage and other portfolio companies. Previously, until 3Q20 reporting period, the private portfolio was presented across the late stage (Water Utility, Housing Development, P&C Insurance), early stage (Renewable Energy, Hospitality and Commercial Real Estate, Education, Beverages) and pipeline (Auto Service, Digital Services) businesses. The NAV statement below reflects the revised portfolio breakdown, in which the Housing Development, Hospitality and Commercial Real Estate, Beverages, Auto Service and Digital Services businesses are now included in the "other" category.

 

The FY20 NAV Statement shows the development of NAV since 31-Dec-19 (2020 numbers are unaudited):

GEL '000, unless otherwise noted	Dec-19	1. Value creation[49]	2a. Investment	2b. Buyback	2c. Dividend	2d. GHG de-listing[50]	3.Operating expenses	4. Liquidity/ FX/Other	Dec-20	Change %
Listed Portfolio Companies
Georgia Healthcare Group (GHG)	430,079	(195,347)	138,265	-	-	(372,997)	-	-	-	-100.0%
Bank of Georgia (BoG)	597,735	(66,177)	-	-	-	-	-	-	531,558	-11.1%
Total Listed Portfolio Value	1,027,814	(261,524)	138,265	-	-	(372,997)	-	-	531,558	-48.3%
Listed Portfolio value change %		-25.4%	13.5%	0.0%	0.0%	-36.3%	0.0%	0.0%	-48.3%
Private Portfolio Companies
Large Companies	648,893	859,545	-	-	(24,943)	372,997	-	1,745	1,858,237	NMF
Healthcare Services	-	393,797	-	-	-	177,859	-	-	571,656	NMF
Retail (Pharmacy)	-	374,322	-	-	-	178,423	-	-	552,745	NMF
Water Utility	483,970	433	-	-	(15,000)	-	-	1,745	471,148	-2.6%
Insurance (P&C and Medical)	164,923	90,993	-	-	(9,943)	16,715	-	-	262,688	59.3%
Of which, P&C Insurance	164,923	42,826	-	-	(9,943)	-	-	-	197,806	19.9%
Of which, Medical Insurance	-	48,167	-	-	-	16,715	-	-	64,882	NMF
Investment Stage Companies	163,150	98,730	44,501	-	(4,927)	-	-	1,510	302,964	85.7%
Renewable Energy	106,800	62,169	44,350	-	(4,927)	-	-	1,510	209,902	96.5%
Education	56,350	36,561	151	-	-	-	-	-	93,062	65.1%
Other Companies	413,226	(217,266)	11,899	-	-	-	-	7,070	214,929	-48.0%
Total Private Portfolio Value	1,225,269	741,009	56,400	-	(29,870)	372,997	-	10,325	2,376,130	93.9%
Private Portfolio value change %		60.5%	4.6%	0.0%	-2.4%	30.4%	0.0%	0.8%	93.9%
Total Portfolio Value (1)	2,253,083	479,485	194,665	-	(29,870)	-	-	10,325	2,907,688	29.1%
Total Portfolio value change %		21.3%	8.6%	0.0%	-1.3%	0.0%	0.0%	0.5%	29.1%
Net Debt (2)	(493,565)	-	(57,684)	(6,033)	29,870	-	(19,455)	(151,132)	(697,999)	41.4%
of which, Cash and liquid funds	211,889	-	(57,684)	(6,033)	29,870	-	(19,455)	16,702	175,289	-17.3%
of which, Loans issued	151,884	-	-	-	-	-	-	(42,901)	108,983	-28.2%
of which, Gross Debt	(857,338)	-	-	-	-	-	-	(124,933)	(982,271)	14.6%
Net other assets/ (liabilities) (3)	(5,650)	-	1,284	-	-	-	(12,681)	19,650	2,603	-146.1%
of which, share-based comp.	-	-	-	-	-	-	(12,681)	12,681	-	0.0%
Net Asset Value (1)+(2)+(3)	1,753,868	479,485	138,265	(6,033)	-	-	(32,136)	(121,157)	2,212,292	26.1%
NAV change %		27.3%	7.9%	-0.3%	0.0%	0.0%	-1.8%	-6.9%	26.1%
Shares outstanding49	37,441,971	-	7,734,010	(173,076)	-	-	-	974,342	45,977,247	22.8%
Net Asset Value per share, GEL	46.84	12.81	(4.96)	0.06	0.00	0.00	(0.86)	(5.78)	48.12	2.7%
NAV per share, GEL change %		27.3%	-10.6%	0.1%	0.0%	0.0%	-1.8%	-12.3%	2.7%

 

Basis of presentation

This announcement contains unaudited financial results presented in accordance with International Financial Reporting Standards ("IFRS") and International Accounting Standards ("IAS") adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the European Union and in conformity with the requirements of the Companies Act 2006 and International Financial Reporting Interpretations Committee ("IFRIC") interpretations issued by the International Accounting Standards Board ("IASB") effective for 2020 reporting. The financial results are unaudited and derived from management accounts.

The information in this Announcement in respect of full year 2020 preliminary results, which was approved by the Board of Directors on 23 February 2021, does not constitute statutory accounts as defined in Section 435 of the UK Companies Act 2006. The Group's financial statements for the year ended 31 December 2019 were filed with the Registrar of Companies, and the audit reports were unqualified and contained no statements in respect of Sections 498 (2) or (3) of the UK Companies Act 2006. The financial statements for the year ended 31 December 2020 will be included in the Annual Report and Accounts to be published in March 2021 and filed with the Registrar of Companies in due course.

Under IFRS 10, Georgia Capital PLC meets the "investment entity" definition and does not consolidate its portfolio companies, instead the investments are measured at fair value. Our Group level discussion is therefore based on the IFRS 10 investment entity accounts.

Net Asset Value statement, as included in notes to IFRS financial statements (page 25 in this document), summarises the Group's equity value and drivers of related changes between the reporting periods. Georgia Capital PLC holds a single investment -- in JSC Georgia Capital (an investment entity on its own) - which in turn owns a portfolio of investments, each measured at fair value. Georgia Capital PLC measures its investment in JSC Georgia Capital at fair value through profit and loss under IFRS, estimated with reference to JSC Georgia Capital's own investment portfolio value as offset against its net debt. NAV is calculated at stand-alone GCAP level, which represents the aggregation of the stand-alone assets and liabilities of Georgia Capital PLC and JSC Georgia Capital.

The income statement presents the Group's results of operations for the reporting period. As we conduct most of our operations through JSC Georgia Capital, through which we hold our portfolio companies, the IFRS results provide little transparency on the underlying trends. To enable a comprehensive view of the combined operations of Georgia Capital PLC and JSC Georgia Capital (together referred to herein as "GCAP") as if it were one holding company, we adjust the accounts ("adjusted IFRS 10 Income Statement"). For details on the methodology underlying the preparation of the adjusted income statement, please refer to page 90 in Georgia Capital PLC 2019 Annual report. A full reconciliation of the adjusted income statement, to the IFRS income statement is provided on page 21. Our adjusted IFRS 10 income statement may be viewed as alternative performance measure (APM). 

Additionally, for the majority of our portfolio companies the fair value of our equity investment is determined by the application of a market approach (listed peer multiples and precedent transactions) and an income approach (DCF). Under the market approach, listed peer group earnings multiples are applied to the trailing twelve month (LTM) stand-alone IFRS earnings of the relevant business. Under the discounted cash flow (DCF) valuation method, fair value is estimated by deriving the present value of the business using reasonable assumptions of expected future cash flows and the terminal value, and the appropriate risk-adjusted discount rate that quantifies the risk inherent to the business. As such, the stand-alone IFRS results and developments behind IFRS earnings of our portfolio companies are key drivers in their valuations. Following the Group discussion, we therefore also present IFRS financial statements for material companies and a related brief results discussion.

Summary of valuation methodology for our investment portfolio

The fair values of the four large private portfolio companies at year-end 2020 were assessed by an independent valuation company, while the valuations were performed internally at year-end 2019 (excluding GHG). The combination of income approach (DCF) and market approach (listed peer multiples and in some cases precedent transactions) was applied consistently under both, internal and external valuation approaches. However, the independent valuation company's approach is more highly weighted towards DCF, representing a change from the previous internal valuation methodologies. More details on the methodology underlying the independent valuation is provided on pages 25-28 in fair value measurement note to IFRS financial statements and also will be provided in the Annual Reports and Accounts. Going forward, we intend to provide independent valuations of the large portfolio companies semi-annually.

 

 

 

GLOSSARY

1.     APM - Alternative Performance Measure.

2.     GCAP refers to the aggregation of stand-alone Georgia Capital PLC and stand-alone JSC Georgia Capital accounts.

3.     Georgia Capital and "the Group" refer to Georgia Capital PLC and its portfolio companies as a whole.

4.     NMF - Not meaningful.

5.     NAV - Net Asset Value, represents the net value of an entity and is calculated as the total value of the entity's assets minus the total value of its liabilities.

6.     LTM - last twelve months.

7.     NTM - next twelve months.

8.     EBITDA - Earnings before interest, taxes, non-recurring items, FX gain/losses and depreciation and amortisation; The Group has presented these figures in this document because management uses EBITDA as a tool to measure the Group's operational performance and the profitability of its operations. The Group considers EBITDA to be an important indicator of its representative recurring operations.

9.     ROIC - return on invested capital is calculated as EBITDA less depreciation, divided by aggregate amount of total equity and borrowed funds.

10.  Loss ratio equals net insurance claims expense divided by net earned premiums.

11.  Expense ratio in P&C Insurance equals sum of acquisition costs and operating expenses divided by net earned premiums.

12.  Combined ratio equals sum of the loss ratio and the expense ratio in the insurance business.

13.  ROAE - Return on average total equity (ROAE) equals profit for the period attributable to shareholders divided by monthly average equity attributable to shareholders of the business for the same period.

14.  Net investment - gross investments less capital returns (dividends and sell-downs).

15.  EV - enterprise value.

16.  Liquid assets & loans issued include cash, marketable debt securities and issued short-term loans at GCAP level.

17.  Total return / value creation - total return / value creation of each portfolio investment is calculated as follows: we aggregate a) change in beginning and ending fair values, b) gains from realised sales (if any) and c) dividend income during period. We then adjust the net result to remove capital injections (if any) to arrive at the total value creation / investment return.

18.  WPP - Wind power plant.

19.  HPP - Hydro power plant.

20.  PPA - Power purchase agreement.

21.  Number of shares outstanding - Number of shares in issue less total unawarded shares in JSC GCAP's management trust.

 

ABOUT GEORGIA CAPITAL PLC

Georgia Capital PLC (LSE: CGEO LN) is a platform for buying, building and developing businesses in Georgia (together with its subsidiaries, "Georgia Capital" or "the Group"). The Group's primary business is to develop or buy businesses, help them institutionalise their management and grow them into mature businesses that can further develop largely on their own, either with continued oversight or independently. Once Georgia Capital has successfully developed a business, the Group actively manages its portfolio to determine each company's optimal owner. Georgia Capital will normally seek to monetise its investment over a 5-10 year period from initial investment. 

Georgia Capital currently has six private businesses: (i) a healthcare services business; (ii) a water utility business; (iii) a retail (pharmacy) business, (iv) an insurance business (P&C and medical insurance); (v) a renewable energy business and (vi) an education business; We also hold other small private businesses across different industries in Georgia and a 19.9% equity stake in LSE premium-listed Bank of Georgia Group PLC ("BoG"), a leading universal bank in Georgia.

Forward looking statements

This announcement contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Georgia Capital PLC believes that the expectations and opinions reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, certain of which are beyond our control, include, among other things: impact of COVID-19; regional instability; regulatory risk across a wide range of industries; investment risk; liquidity risk; portfolio company strategic and execution risks; currency fluctuations, including depreciation of the Georgian Lari, and macroeconomic risk; and other key factors that could adversely affect our business and financial performance, which are contained elsewhere in this document and in our past and future filings and reports and also the 'Principal Risks and Uncertainties' included in 1H20 results announcement and Georgia Capital PLC's Annual Report and Accounts 2019. No part of this document constitutes, or shall be taken to constitute, an invitation or inducement to invest in Georgia Capital PLC or any other entity, and must not be relied upon in any way in connection with any investment decision. Georgia Capital PLC and other entities undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Nothing in this document should be construed as a profit forecast.

Disclaimer

Georgia Capital engaged Duff & Phelps, a third-party independent valuation firm to provide a range of fair values of certain subject investments. For the quarter ended 31 December 2020, Georgia Capital asked the independent valuation firm to independently estimate a range of fair value for 100 percent of Georgia Healthcare Group ("GHG"), JSC Insurance Company Aldagi Group ("Aldagi") and Georgia Global Utilities ("GGU"). Duff & Phelps performed limited procedures and applied their judgement to estimate fair value range based on the facts and circumstances known to them as at the valuation date, 31 December 2020. The analysis performed by Duff & Phelps was based upon data and assumptions provided by Georgia Capital and received from third party sources, which the independent valuation firm relied upon as being accurate without independent verification. The advice of the third party independent valuation firm is one input that the Georgia Capital considered for determining the fair value of GHG, Aldagi and GGU, for which the Company is ultimately and solely responsible. In this context, Duff & Phelps' role as independent valuation service provider did not constitute an endorsement of Georgia Capital either from a financial or operational point of view, nor did they provide a transaction, fairness or solvency opinion. The results of the independent valuation report should not be relied upon by anyone for any investment or transaction purpose related to the Company or any underlying investments.

 

 

COMPANY INFORMATION

 

Georgia Capital PLC

 

Registered Address

84 Brook Street

London W1K 5EH

United Kingdom

www.georgiacapital.ge 

Registered under number 10852406 in England and Wales

 

Stock Listing

London Stock Exchange PLC's Main Market for listed securities

Ticker: "CGEO.LN"

 

Contact Information

Georgia Capital PLC Investor Relations

Telephone: +44 (0) 203 178 4052; +995 322 000000

E-mail: ir@gcap.ge

 

Auditors

Ernst & Young LLP

1 More London Place

London, SE1 2AF

United Kingdom

 

Registrar

Computershare Investor Services PLC

The Pavilions

Bridgwater Road

Bristol BS13 8AE

United Kingdom

 

Please note that Investor Centre is a free, secure online service run by our Registrar, Computershare, 

giving you convenient access to information on your shareholdings. 

Investor Centre Web Address - www.investorcentre.co.uk. 

Investor Centre Shareholder Helpline - + 44 (0) 370 702 0176

 

Share price information

Shareholders can access both the latest and historical prices via the website 

www.georgiacapital.ge